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A B S T R A C T
A plethora of studies indicate the important role of cAMP and cGMP cascades in neuronal plasticity and memory
function. As a result, altered cyclic nucleotide signaling has been implicated in the pathophysiology of mnemonic
dysfunction encountered in several diseases. In the present review we provide a wide overview of studies re-
garding the involvement of cyclic nucleotides, as well as their upstream and downstream molecules, in phy-
siological and pathological mnemonic processes. Next, we discuss the regulation of the intracellular con-
centration of cyclic nucleotides via phosphodiesterases, the enzymes that degrade cAMP and/or cGMP, and via
A-kinase-anchoring proteins that refine signal compartmentalization of cAMP signaling. We also provide an
overview of the available data pointing to the existence of specific time windows in cyclic nucleotide signaling
during neuroplasticity and memory formation and the significance to target these specific time phases for im-
proving memory formation. Finally, we highlight the importance of emerging imaging tools like Förster re-
sonance energy transfer imaging and optogenetics in detecting, measuring and manipulating the action of cyclic
nucleotide signaling cascades.
1. Introduction
Cyclic nucleotides are the “second messengers” that connect the
extracellular environment to the intracellular environment and trans-
duce the signal of the “first messenger” like hormones and neuro-
transmitters. The initial second messenger described was the cyclic
adenosine monophosphate (cAMP) in 1971 by Earl W. Sutherland Jr.
who won the ‘Nobel Prize in Physiology or Medicine’ for his discoveries
concerning the “mechanism of the action of the hormones”. The same
prize was awarded 27 years later to Robert F. Furchgott, Louis J.
Ignarro and Ferid Murad for their work regarding the role of nitric
oxide (NO) and cyclic guanosine monophosphate (cGMP) as signaling
molecules in the cardiovascular system. The importance of cAMP in
signal transduction was highlighted by the work of Eric Kandel who
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described the importance of the synapses in memory formation,
showing that activation of cAMP and its downstream kinases is essential
for synaptic plasticity. Also Eric Kandel together with Arvid Carlsson
and Paul Greengard received the ‘Nobel Prize in Physiology or
Medicine’ for his seminal work on memory processes and function. Over
the past decades, an abundance of studies emerged showing the role of
cyclic nucleotides in cellular mechanisms related to memory function,
including signal transduction, neuroplasticity, metabolism, gene tran-
scription and cell growth (Box 1).
The present review will summarize available data and discuss the
role of cyclic nucleotides in mnemonic processes. Additionally, up-
stream and downstream molecules involved in the cyclic nucleotide
signaling cascade are discussed. Accordingly, the existence of time
windows and their action is discussed, and the resulting significance to
target specific windows in order to improve memory performance.
Finally, we highlight the significance of emerging imaging tools in
manipulating and determining the action of cyclic nucleotides signaling
cascades.
2. Second messenger cascades
2.1. The cAMP pathway
The second messenger cAMP is synthetized from adenosine tripho-
sphate (ATP) by adenylate cyclase (AC). ACs are transmembrane en-
zymes regulated by G-protein coupled receptors (GPCR). There have
been identified nine unique membrane isoforms of AC, which are re-
ferred to as AC1-9, and one soluble form (sAC). Neurotransmitters can
activate or inhibit AC signaling into the cells via GPCR. In basal con-
ditions, GPCR are heterotrimers consisting of 3 subunits: α, β, γ.
Activation of these receptors by their respective ligand (e.g. neuro-
transmitter or hormone) results in dissociation of the subunits into a
free α subunit (Gα) and a free βγ subunit complex (Gβγ). The Gα can
directly bind to AC, causing its activation (Gαs) or inhibition (Gαi).
Increased production of cAMP triggers a multitude of cellular reactions
coordinated by its downstream effectors, including protein kinase A
(PKA), also named c-AMP dependent protein kinase (cAPK), cyclic
nucleotide-gated channels (CNGC) and exchange protein directly acti-
vated by cAMP (Epac). Nevertheless, the most widely known and stu-
died effector mediating intracellular cAMP signaling is PKA. Activated
PKA can phosphorylate several cytosolic and nuclear substrates. A
major event facilitating neuronal plasticity is phosphorylation and
subsequent activation of cAMP response element binding protein
(CREB) at Ser133 by PKA. Phosphorylated CREB (p-CREB) is an acti-
vated transcription factor that binds the cAMP response element (CRE),
initiating the transcription of specific genes coding for neurotransmitter
receptors such as ionotropic α-amino-3-hydroxy-5-methyl-4-iso-
xazolepropionic acid (AMPA) receptors or growth factors including
brain-derived neurotrophic factor (BDNF) (Bitner, 2012). Termination
of PKA activity occurs via a negative feedback mechanism. Among the
substrates that undergo phosphorylation by PKA are the phosphodies-
terase enzymes (PDEs) that degrade cyclic nucleotides. Upon activation,
PDEs catalyze the conversion of cAMP to ATP, reducing cAMP levels
and bringing PKA back to its inactive state. PKA provides an additional
negative feedback in the AC/cAMP signaling cascade by inhibiting the
enzymatic activity of AC5 and AC6 (Chen et al., 1997; Iwami et al.,
1995).
Despite the traditionally described AC/cAMP/PKA pathway that
leads to CREB phosphorylation, it has been shown that cAMP/PKA
could also indirectly lead to CREB phosphorylation via the extracellular
signal-related kinase (ERK). In response to neurotransmitter release, the
concentration of intracellular calcium (Ca2+) is raised leading to the
increased phosphorylation of ERK via the traditional Ras/Raf/MEK/
ERK pathway (Impey et al., 1999). Subsequently, CREB is phosphory-
lated by the ERK-activated Rsk family of protein kinases (Impey et al.,
1998; Xing et al., 1996). More precisely, Rsk2 is implicated in the Ca2+-
stimulated CREB phosphorylation in cell cultures (Impey et al., 1998).
The impact of ERK on CREB phosphorylation is also supported by the
observation that inhibition of ERK reduces CREB phosphorylation
(Impey et al., 1998). Additionally, it has been shown in neuronal cell
cultures that ERK could be activated in a Ras-independent fashion via
PKA (Grewal et al., 2000). Based on that model, PKA was assumed to
promote activation of the small G-protein Rap1 and the downstream
kinase B-Raf creating the Rap1/B-Raf signaling complex that results in
ERK activation (Grewal et al., 2000). However it is highly possible that
Epacs also participate in the Rap1-mediated activation of ERK, since
Rap-1 is activated by Epacs (Kitayama et al., 1989). This pathway could
work in tandem with the previously described pathway in facilitating
neuronal signaling upon an extracellular stimulus. Finally, except for
the direct role of PKA in activating ERK, translocation of ERK to the
nucleus requires PKA activity (Impey et al., 1998).
Additionally, there seems to be an interplay between the cAMP
second messenger system and the phosphoinositol second messenger
system. Binding of a ligand to the Gαq-linked GPCR receptor leads to
activation of phospholipase C (PLC) which hydrolyzes phosphatidyli-
nositol 4,5-biphosphate (PIP2). The latter leads to the production of
two intracellular mediators inositol-1,4,5,triphosphate (IP3) and dia-
cylglycerol (DAG). IP3 diffuses rapidly into the cytosol and binds to the
IP3 receptors of the endoplasmic reticulum, promoting the release of
Ca2+. DAG is retained in the membrane where it interacts with and
activates protein kinase C (PKC) in the presence of Ca2+. Of note, the
source of Ca2+ could also be extracellular after stimulation of an io-
notropic receptor [e.g. N-methyl-D-aspartate (NMDA) receptor]. Upon
activation, PKC can activate ERK by acting on Raf as part of the Ras/
Raf/MEK/ERK pathway (Ueda et al., 1996). Additionally, PKC stimu-
lates activation of AC2, AC4, AC7 (Cooper, 2003; Schallmach et al.,
2006; Tabakoff et al., 2001) and inhibits AC9 (Cumbay and Watts,
2004) creating a regulatory loop between PKC and cAMP/PKA sig-
naling pathway. Elevated intracellular Ca2+ could also result in the
activation of specific Ca2+/calmodulin-dependent protein kinase II
(CaMKII), which can stimulate the insertion of AMPA receptors in the
postsynaptic membrane (Sweatt, 1999). In addition, CaMKII can also
activate PKA indirectly via activation of AC and subsequent production
of cAMP (Mizunami et al., 2014).
Box 1
Different stages of plasticity and memory.
Synaptic potentiation represents an experimental model for examining the synaptic basis of learning and memory. Depending on the duration,
synaptic potentiation can be divided into short-term potentiation (STP), lasting<1 h, and long-term potentiation (LTP), lasting up to 8 h.
Subsequently, LTP can be divided in 3 phases with distinct underlying mechanisms; LTP1 that dependents on activation of kinases, LTP2 that is
the long-lasting phase and dependents on protein translation form pre-existing mRNA and LTP3 which requires gene transcription and sub-
sequent protein translation (Bliss and Collingridge, 1993; Reymann and Frey, 2007). Early phase LTP (E-LTP) or LTP1 usually lasts less than 3
h while late LTP (L-LTP) or LTP3 could last up to 8 h. With respect to mnemonic stages, it is suggested that E-LTP is equivalent to short-term
memory (STM) and L-LTP is related to long-term memory (LTM) (Izquierdo et al., 2002), while an intermediate-term memory (IM) phase is
similar to LTP2. It could be proposed that STM could be converted to IM via early consolidation and from IM to LTM via late consolidation
(Reneerkens et al., 2009).
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Fig. 1. Cyclic nucleotide signaling pathways at the pre- and post-synaptic cell. The cyclic adenosine monophosphate (cAMP) and cyclic guanylate mono-
phosphate (cGMP) molecules are generated by the enzymes adenylate cyclase (AC) and guanylate cyclase (GC), respectively. The majority of ACs (AC1-9) is
transmembrane and is regulated via G-protein coupled receptors (GPCRs). Binding of a neurotransmitter to GPCR could lead to dissociation of Gαs from the Gβγ
subunit complex. In turn, binding of Gαs to ACs could lead to their activation. Apart from Gα, ACs are regulated by other molecules, leading to their classification into
four groups. AC1, 3 and 8 (group I) are activated by Ca2+ and inhibited by Gβγ subunit. AC2, 4 and 7 (group II) are stimulated by Gβγ subunit and protein kinase C
(PKC). AC5 and 6 (group III) are inhibited by Ca2+ and finally AC9 (group IV) is inhibited by calcineurin (CaN) and PKC.
Production of cAMP leads to activation of its downstream effectors exchange protein directly activated by cAMP (Epac) and protein kinase A (PKA) that will
eventually promote protein synthesis via cAMP-responsive element binding protein (CREB). Another kinase that could phosphorylate CREB is extracellular signal-
activated kinase (ERK). In addition to its activation by Ca2+, ERK can be activated by the Rap1/B-Raf/MEK signaling complex. Rap1 can be activated either by PKA
or by Epac, positioning ERK signaling downstream of cAMP. Apart from its role in long-term plasticity via induction of protein synthesis, PKA also participates in
short-term plasticity. This is achieved via activation of the protein phosphatase inhibitor-1 (I-1) that relieves the inhibition of calmodulin-dependent protein kinase
(CaMKII) from protein phosphatase-1 (PP1).
cGMP is produced by the enzyme GC that in the hippocampus exists mainly in a soluble form. The main ligand of soluble GC (sGC) is nitric oxide (NO), a gaseous
molecule produced via the enzyme nitric oxide synthase (NOS). Production of cGMP leads to activation of protein kinase G (PKG) that upregulates CREB phos-
phorylation. Direct phosphorylation of CREB via PKG has been only shown in vitro. It is also suggested that PKG could promote CREB phosphorylation indirectly via
ERK.
Another intracellular cascade that interacts with the cyclic nucleotide cascade is the phosphoinositol second messenger system. Binding of a ligand to the Gαq-linked
GPCR receptor leads to activation of phospholipase C (PLC) that eventually promotes the production of two intracellular mediators; inositol-1,4,5,triphosphate (IP3)
and diacylglycerol (DAG). IP3 facilitates the release of Ca2+ from intracellular compartments, whereas DAG activates PKC. Increase in intracellular Ca2+ levels could
also result from stimulation of the N-methyl-D-aspartate (NMDA) receptor or the voltage-gated calcium channels (VGCC). Elevated Ca2+ into the cell facilitates
activation of CaMKII that could subsequently activate the cAMP signaling cascade.
A point of convergence of the above cascades in the post-synaptic cell is the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. PKA and PKG
phosphorylate AMPA receptors at the same site (S845) promoting their trafficking to the synapse. Additionally, insertion of AMPA receptors into the membrane is
facilitated by their phosphorylation by CaMKII and PKC. Finally, new AMPA receptors are synthesized after CREB activation.
Major regulation of the intracellular concentration of cyclic nucleotides is provided by phosphodiesterases (PDEs), a family of eleven members (PDE1-11) that
hydrolyzes cAMP and/or cGMP. The dual substrate PDE1, 2, 3, 10, 11 could degrade both cyclic nucleotides, while PDE4, 7, 8 are cAMP-specific and PDE5, 6, 9 are
cGMP-specific.
At the pre-synaptic cell, activation of cAMP and cGMP cascades could lead to release of neurotransmitters, more specifically glutamate (green triangles), at the
E.K. Argyrousi, et al. Neuroscience and Biobehavioral Reviews 113 (2020) 12–38
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Except for the above mechanisms that represent the postsynaptic
action of the cAMP signaling pathway, a presynaptic role has also been
identified. Presynaptically, cAMP is mainly involved in synthesis, re-
lease and metabolism of neurotransmitters like glutamate and dopa-
mine (Rodríguez-Moreno and Sihra, 2013; Schoffelmeer et al., 1985),
most likely via a presynaptic CaMKII/AC/cAMP/PKA cascade. Ad-
ditionally, presynaptic cAMP levels are also regulated by GPCRs in-
dependent of CAMKII, including metabotropic glutamate receptors
(Schoepp, 2001) and cannabinoid receptors (Alonso et al., 2017;
Chevaleyre et al., 2007) (Fig. 1).
2.2. The cGMP pathway
In the same line as cAMP, cGMP production is catalyzed by the
enzyme guanylate cyclase (GC) from guanosine triphosphate (GTP). GC
exists in two forms; either a membrane bound particulate GC (pGC) or a
soluble GC (sGC) form. The seven isoforms of pGC are mainly expressed
in the periphery and their distribution in the brain is restricted to the
pineal gland, the cerebellum, the pituitary and the olfactory epithelium.
sGC is widely distributed in the brain including the hippocampus,
striatum, cerebral cortex and locus coeruleus (Matsuoka et al., 1992). In
the brain, intracellular responses to neurotransmitters are mainly at-
tributed to activation of sGC, while the pGC responds to natriuretic
peptides (Schulz et al., 1991). It has been proposed that several neu-
rotransmitters could activate sGC for the production of cGMP. However
the most potent activator is NO which is synthesized from the enzyme
nitric oxide synthase (NOS) in response to elevated Ca2+ levels. Ca2+/
calmodulin binds to the catalytic domain of NOS which catalyzes the
synthesis of NO from L-arginine. At nanomolar concentrations, NO
binds to sGC and rapidly increases the catalytic conversion of GTP to
cGMP (Ignarro et al., 1982; Stone and Marletta, 1996). The main in-
tracellular effectors conveying the NO-sGC signal include cGMP-gated
cation channels, protein kinase G (PKG; or cGMP-dependent protein
kinase (cGK)) and phosphodiesterases (cGMP-specific phosphodies-
terases and cGMP-regulated phosphodiesterases that have allosteric
sites for cGMP). From the effectors above, PKG has been most ex-
tensively studied and several lines of evidence implicate the cGMP/PKG
pathway in the modulation of synaptic transmission.
NO acts as retrograde messenger and stimulates presynaptic sGC to
induce production of cGMP, which eventually leads to the production of
PKG. Additionally, in the presynaptic terminal, cGMP can influence the
release of neurotransmitters, like glutamate and dopamine (Arancio
et al., 1996; Sanchez et al., 2002). Postsynaptically it has been shown
that upregulation of the cGMP/PKG pathway results in CREB phos-
phorylation (Lu and Hawkins, 2002; Lu et al., 1999). The underlying
mechanism of this relationship is yet elusive. in vitro studies conducted
with cell lines showed that, although PKG could phosphorylate a syn-
thetic peptide of CREB that contains the Ser133 sequence, the reaction
occurs at a lower rate in comparison to PKA (Colbran et al., 1992).
Therefore, the general belief is that the cGMP/PKG pathway mediates
CREB phosphorylation via an indirect mechanism, which is also sup-
ported by the fact that there is no evidence showing PKG nuclear lo-
calization. PKG could also facilitate CREB phosphorylation by stimu-
lating the release of Ca2+ from ryanodine-sensitive stores (Lu and
Hawkins, 2002). In that respect, CREB phosphorylation can be medi-
ated by Ca2+-sensitive ERK via the CREB kinase Rsk2 (Impey et al.,
1998). Finally, PKG has been shown to stimulate polymerization of
actin filaments at both pre- and post-synaptic cells, regulating ag-
gregation of synaptic molecules, e.g. AMPA receptors at the post-
synaptic cell (Wang et al., 2005a) (Fig. 1).
3. Adenylate cyclases: regulation, tissue distribution and
participation in neuronal function
ACs are the key enzymes in the initiation of cAMP signaling since
they catalyze the conversion of ATP to cAMP. Based on their regulation,
membrane-bound ACs can be divided in four groups (Table 1). Group I
consists of AC1, AC3 and AC8, which are activated by Ca2+ and
CaMKII. Additionally, they are synergistically activated by Gαs (Cali
et al., 1996; Krupinski et al., 1992; Tang and Gilman, 1991), while they
are inhibited by Gβγ (Steiner et al., 2006; Tang and Gilman, 1991; Tang
et al., 1991). Although AC3 is grouped along with AC1 and AC8 as
Ca2+-activated AC, this classification is based on one study showing
that AC3 can be activated by high levels of Ca2+, but only when the co-
factors forskolin or GppNHP (a non-hydrolysable GTP analog) are
present (Choi et al., 1992). The fact that in cell lines only AC1 and AC8
are stimulated in physiologically relevant concentrations of Ca2+,
questions the co-categorization of AC3 in the same group as AC1 and
AC8 (Fagan et al., 1996). Group II contains the Ca2+ insensitive AC2,
AC4 and AC7, which are stimulated by Gβγ subunits (Feinstein et al.,
1991; Gao and Gilman, 1991; Tang and Gilman, 1991; Yoshimura et al.,
1996). Group III contains AC5 and AC6 which are inhibited by Ca2+
and the Gαi (Ishikawa et al., 1992; Katsushika et al., 1992; Premont
et al., 1992; Yoshimura and Cooper, 1992), and group IV contains AC9,
which is the only AC isoform that is not responsive to forskolin, and
undergoes negative regulation by calcineurin (CaN) (Antoni et al.,
synaptic cleft. AC is activated via Ca2+ /CaMKII, while sGC is activated by NO that is produced in the postsynaptic cell and acts as a retrograde messenger to the pre-
synaptic cell. Activated PKG could phosphorylate vasodilator-stimulated phosphoprotein (VASP) at both the pre-and post-synaptic cell (not shown) regulating actin
polymerization. As with the post-synaptic cell, the main regulation of cyclic nucleotide concentration at the pre-synaptic cell is provided by PDEs.
Table 1
Summary of the different types of adenylate cyclases, their differential regulation, region-specific expression and function in the brain. AC = adenylate cyclase,
CA1=Cornu Ammonis 1, CaMK = calmodulin-dependent protein kinase, DG = dentate gyrus.
Type Group Isoform Regulation Hippocampal/brain expression CNS function
Membrane-bound AC Group 1 AC1, AC3, AC8 Ca2+, CaMK, synergistically activated by
Gαs, inhibited by Gβγ
AC1, AC3, AC8 highly expressed in CA1 subregion;
AC1 also expressed in DG
Diverse, including
memory








Group 4 AC9 Unresponsive to forskolin, negatively
regulated by calcineurin
AC9 highly expressed in all three CA subregions
and in the DG
Diverse, including
memory
Soluble AC n.a. Only 1 soluble
form
Activated by bicarbonate Nucleus, mitochondria and centrosome Cell division
E.K. Argyrousi, et al. Neuroscience and Biobehavioral Reviews 113 (2020) 12–38
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1998; Paterson et al., 1995) (Fig. 1). Finally, the sAC is located in the
nucleus, mitochondria and centrosome during cell division and it is
activated by bicarbonate. Changes in bicarbonate reflect changes in pH
and carbon dioxide indicating that unlike membrane AC that responds
to extracellular signals, sAC responds to intrinsic cellular signals
(Zippin et al., 2003).
A detailed analysis of the expression of the different AC isoforms in
mouse brain, revealed that all isoforms are expressed in neuronal tissue
with the exception of AC7, which is undetectable in the brain, and AC4
that is mainly expressed in vessels (Visel et al., 2006). With respect to
their expression pattern in the hippocampus, it was shown that AC1,
AC2 and AC8 are highly expressed in Cornu Ammonis 1 (CA1), while
AC1 and AC2 are also expressed in dentate gyrus (DG). AC5 and AC6
are mainly expressed in the CA2 subregion. Interestingly, AC9 is
abundant in the hippocampus and it is the only isoform highly ex-
pressed in all three CA subregions and in the DG (Antoni et al., 1998).
Based on the above observation, the authors suggested regional co-lo-
calization and complementation in the expression pattern of ACs that
share the same regulatory mechanism in the hippocampus. Ad-
ditionally, there seems to be complementation in the expression of
group I ACs, with AC1 expression prevailing in the DG, while AC8 is
mainly restricted to CA1. Except for the distinct cellular localization,
AC1 and AC8 also display distinguished patterns of subcellular ex-
pression. In particular, AC1 is abundantly expressed in the postsynaptic
density and extrasynaptic sites, whereas AC8 is mainly expressed in the
presynaptic active zone and extrasynaptic fractions (Conti et al., 2007).
Despite the importance of the above findings regarding the expression
of AC, they do not provide evidence for the expression of functional AC
enzymes in the different subregions of the hippocampus (Visel et al.,
2006; Willoughby and Cooper, 2007).
3.1. Role of ACs in synaptic plasticity and memory
ACs have been shown to be involved in plasticity and hippocampus-
dependent forms of memory. Consistent with their expression and dis-
tribution in the hippocampus, the involvement of the Ca2+-stimulated
AC1 and AC8 is extensively studied in LTP studies and behavioral
paradigms. Mice that overexpress the AC1 encoding gene Adcy1
showed sustained LTP (e.g. L-LTP) after an induction protocol that
normally induces only E-LTP (Wang et al., 2004), and additionally
exhibited impairments in long-term depression (LTD) (Zhang and
Wang, 2013). This observation was accompanied by a pro-cognitive
effect in the object recognition test (ORT), in which transgenic mice
were able to remember the objects after a long interval between the two
trials (Wang et al., 2004). These results indicate that increased activa-
tion of AC1 could convert the initial short-term memory (STM) into a
more stable long-term memory (LTM) that lasts up to days. Ad-
ditionally, the Adcy1-overexpressing mice exhibited lower rates of fear
memory extinction. The authors attributed the latter finding to in-
creased ERK and CREB phosphorylation that could result in enhanced
initial memory formation and therefore hampered extinction (Wang
et al., 2004). Intriguingly, another study showed that AC1-over-
expressing mice showed better memory flexibility in a spatial memory
task, as reflected by their ability to suppress previously learned in-
formation and relearn the task, indicating that the extinction me-
chanism appears to differ in fear and spatial memory (Zhang and Wang,
2013).
Noteworthy is a study from Storm and colleagues in which they
examined the effect of AC1 overexpression in both young and aged mice
(Garelick et al., 2009). As it was expected, young mice showed a su-
perior mnemonic ability in comparison to their aged littermates in
several mnemonic tasks including fear conditioning, object recognition
and spatial memory. Interestingly, AC1 overexpression in aged mice did
not affect their performance in the first two tasks and even resulted in
memory deficits in spatial memory. Considering that basal levels of AC1
activity were downregulated with aging, the above finding seems
initially counterintuitive. Nevertheless, it was also shown that in the
aging brain PKA activity is also downregulated in certain brain areas
(Arnsten et al., 2005; Ramos et al., 2003).Therefore, the negative effect
of AC1 overexpression could be possibly attributed to hyperstimulation
of the cAMP pathwayinagedanimals.
Except for overexpression of the gene, a reversed approach was also
employed in order to investigate the role of Ca2+-stimulated ACs in
plasticity and memory. Early studies showed that knockout (KO) of AC1
impaired the mossy fiber (DG→CA3) LTP, while the perforant path
(entorhinal area→DG) and the Schaffer collateral (CA3→CA1) LTP
were unaffected (Villacres et al., 1998). Despite the fact that AC8
contributes in lesser extent than AC1 to Ca2+-stimulated ACs activity in
the hippocampus, AC8 KO mice manifested the same level of impair-
ments in mossy fiber LTP as AC1 KO mice (Wang et al., 2003). Although
genetic depletion of either AC1 or AC8 did not impair the Schaffer
collateral LTP in the hippocampus, double KO (DKO) mice for both
genes showed deficits in this type of LTP (Wong et al., 1999). DKO mice
also failed to express LTD (Zhang et al., 2011), suggesting that the
action of both Ca2+-stimulated ACs is important for bidirectional sy-
naptic plasticity.
At the behavioral level, KO mice for either AC1 or AC8 displayed
deficits in the Morris water maze (MWM) spatial learning task (Wu
et al., 1995; Zhang et al., 2008). It appears to be a redundancy in the
function of these two isoforms since AC1 or AC8 KO mice did not ex-
hibit memory impairments in passive avoidance learning and con-
textual fear conditioning, while DKO had impaired performance in
these tasks (Wong et al., 1999). Importantly, although AC1 KO mice
exhibited normal acquisition and retrieval of contextual fear memory,
they were unable to sustain it for a long period in comparison to wild
type mice, pointing out the importance of AC1 for memory stability
(Shan et al., 2008). The differential effect of AC1 or AC8 KO mice in
comparison with DKO mice in various learning tasks could be related to
the involvement of different brains areas during each task, as well as
with the distinct distribution of the different Ca2+-stimulated ACs in
the subregions of the hippocampus. For example, it was suggested that
the mRNA of AC1 was increased in the subregion CA1-CA2 of the
hippocampus during the acquisition phase of radial arm water maze
(e.g. a derivative of MWM that assesses reference spatial memory), but
not during the procedural version of the task (Mons et al., 2003). This
regional specificity indicates that formation of spatial and non-spatial
memory requires distinct distribution of Ca2+-stimulated ACs in the
hippocampus (Mons et al., 2003). Finally, impairments in DKO mice
were accompanied by deficits in relearning and suppression of old
spatial memory in the reversal platform test of MWM, outlining again
the importance of balanced cAMP/PKA signaling for strengthening and
weakening of the synapses (Zhang et al., 2011).
Although studies examining the involvement of AC1 or AC8 iso-
forms in plasticity and memory are prevailing, AC3 seems to possess a
unique role in mediating signal transduction. This notion was supported
by its high expression in neuronal cilia (Bishop et al., 2007). Specifi-
cally, in the hippocampus, AC3 is only expressed in the primary cilia of
neurons (Wang et al., 2011). Although the exact role of neuronal cilia in
memory remains elusive, it is hypothesized that neuronal cilia represent
signaling platforms, sub-serving interactions between receptors (Green
and Mykytyn, 2014). It was shown that AC3 KO mice display severe
deficits in short-term object recognition memory. Additionally, the
transgenic mice showed no impairment in a contextual fear con-
ditioning paradigm, but were unable to dissociate the context with the
foot-shock during the extinction paradigm (Wang et al., 2011). There-
fore, the AC3 KO mice appear to have a similar behavioral phenotype
with the AC1 and AC8 KO mice, showing impaired acquisition of spatial
memory and extinction of fear memory. Altogether, these findings
suggest a novel role of AC3 in conjugation with the already established
role of AC1 and AC8 in neuronal function underlying mnemonic pro-
cesses.
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4. Role of PKA in synaptic plasticity and memory
Each PKA is a holoenzyme, consisting of two regulatory (R) and two
catalytic (C) domains. The PKA family is comprised of four R (RIα, RIβ,
RIIα, RIIβ) and three C (Cα, Cβ, Cγ) subunits. The division of PKA into
two classes, PKAI (consisting of RIα and RIβ dimers) and PKAII (con-
sisting of RIIα and RIIβ dimers) has been attributed to the differences in
the R subunits (Table 2). Refined crosstalk between the different intra-
domains of the R subunits ensures efficient regulation of PKA activity in
response to cAMP (McNicholl et al., 2010). Additionally, binding of
cAMP in the two R domains, causes conformational changes leading to
the dissociation of the C subunits from the R subunits (Gibbs et al.,
1992; Taylor et al., 1990). Subsequently, the C subunits could trans-
locate to the nucleus where they catalyze phosphorylation of serine and
threonine residues of several proteins (Abel and Nguyen, 2008). In
addition, recent evidence showed that there is a functional pool of PKA
tetramers in the nucleus that contributes to fast nuclear PKA signaling
(Sample et al., 2012). Since the pioneering work of Kandel in Aplysia
showing the necessity of PKA for consolidation of long-term memories,
several studies established the involvement of PKA signaling in plasti-
city and memory in rodents. More precisely, a great body of literature
supports that PKA activity is important for L-LTP in hippocampal slices.
This observation is supported by both pharmacological and genetic
models showing that inhibition of PKA activity can suppress expression
of L-LTP (Huang and Kandel, 1994; Impey et al., 1996; Nguyen and
Kandel, 1997) and conversely PKA activation can elicit L-LTP (Bach
et al., 1999; Frey et al., 1993). Nguyen and Kandel showed that ap-
plication of the two different PKA inhibitors KT-5720 (inhibits the
catalytic subunit) and Rp-cAMPS (inhibits the regulatory subunit)
during the induction of LTP leads to a rapid decline in the amount of
potentiation (Nguyen and Kandel, 1997). Nevertheless, LTP was un-
affected when the inhibitors were applied 30 min after induction, in-
dicating that PKA recruitment is essential during a defined time
window (Nguyen and Kandel, 1997). Additionally, LTP was declined in
the transgenic mouse model R(AB), that expresses a dominant in-
hibitory form of the regulatory subunit of PKA (Abel et al., 1997), while
in mice lacking the Cβ1 isoform of the Cβ subunit, L-LTP was attenuated
2.5 h after the induction (Qi et al., 1996). Although the above studies
implicate the action of PKA at the L-LTP, the study of Otmakhova et al.
supported the idea that the action of PKA at the postsynaptic cell is not
only restricted to L-LTP, but it is also important for expression of E-LTP
(Otmakhova et al., 2000).
Based on these later observations PKA activity could be involved in
both E-LTP and L-LTP and its action is mediated via phosphorylation of
different substrates. Regarding its role in L-LTP, PKA action seems to be
mediated by CREB phosphorylation and subsequent transcription of
new proteins involved in plasticity (Matsushita et al., 2001; Nguyen
et al., 1994). The mechanism by which PKA is involved in E-LTP is more
unclear, but is thought to require phosphorylation of existing substrates
like AMPA and NMDA receptors. Bidirectional trafficking of AMPA
receptors is important for hippocampal synaptic plasticity and memory
formation (Derkach et al., 2007; Hu et al., 2007; Malenka, 2003).
During LTP, PKA-dependent phosphorylation of GluA1-AMPA receptors
at Ser845 is required for stable LTP and incorporation of GluA1-AMPA
receptors at the synaptic site is blocked by PKA inhibitors (Esteban
et al., 2003). Similarly, PKA activity is also linked to NMDA receptor
phosphorylation and it was shown that phosphorylation of NMDA re-
ceptors by PKA would alter Ca2+ influx via the channel (Skeberdis
et al., 2006).
Apart from the above substrates, activated PKA could facilitate
signal transmission during E-LTP by modulating the activity of protein
kinases and phosphatases. PKA indirectly promotes CaMKII phosphor-
ylation by blocking the activity of protein phosphatase-1 (PP1) through
activation of its endogenous blocker protein phosphatase inhibitor-1 (I-
1) (Blitzer et al., 1998, 1995). Negative feedback in the above cascade is
provided by Ca2+-activated CaN that inhibits I-1 activity and subse-
quently CaMKII phosphorylation (Yakel, 1997).
As with LTP experiments, a variety of rodent behavioral studies
verified that intact PKA signaling is important for formation of LTM.
Disruption of PKA activity either via genetic or via pharmacological
intervention resulted in impairments in long-term spatial memory (Abel
et al., 1997; Sharifzadeh et al., 2005), contextual memory (Abel et al.,
1997; Ahi et al., 2004; Bourtchouladze et al., 1998; Wallenstein et al.,
2002) and aversive memory (Bernabeu et al., 1997a; Quevedo et al.,
2004; Vianna et al., 2000). It was also shown that PKA activity occurs
immediately after training in certain mnemonic tests suggesting it to
play a role in STM. Specifically, PKA and p-CREB immunoreactivity
were increased in the hippocampus immediately, 3 h and 6 h after
training in the step-down inhibitory test, while intra-hippocampus in-
fusion of the PKA inhibitor KT5720 immediately or 3 h or 6 h post-
training impaired the consolidation process of the task (Bernabeu et al.,
1997a). Similarly, two different studies measured PKA levels in the
hippocampus during spatial learning and showed that PKA im-
munoreactivity increases rapidly during training and remained high at
later stages of the acquisition phase (Mizuno et al., 2002; Vázquez et al.,
2000).
A later study from Havekes et al. sought to determine the region
specific changes in the RIIα,β subunits of PKA in the hippocampus
during habituation, training and reversal training in the Y-maze task
(Havekes et al., 2007). Habituation increased PKAIIα,β non-specifically
in all the regions of the hippocampus, suggesting that PKA expression is
elevated at the initial storing phase of spatial memory. During training
and reversal training (day 3) PKAIIα,β expression was increased in CA3
region and DG, while at the end of the procedures (day 7) im-
munoreactivity of PKAIIα,β returned to basal levels. These results in-
dicate that PKA expression in the hippocampus is essential for the ac-
quisition and consolidation of new information, initiating molecular
cascades that eventually will facilitate formation of stable LTM
(Havekes et al., 2007).
Despite the fact that PKA activation facilitates consolidation of
memories in the hippocampus, it was shown that activation of the
cAMP/PKA signaling cascade in the prefrontal cortex could have a
differential effect (Arnsten et al., 2005). Although upregulation of the
cAMP/PKA pathway could improve performance in memory-dependent
tasks, infusion of a PKA activator in the prefrontal cortex of young rats
induced a dose-dependent deficit in delayed-alternation performance
(Taylor et al., 1999). This observation was more profound in aged an-
imals in which cAMP/PKA signaling is reduced in the hippocampus,
while it is elevated in the prefrontal cortex. Consistent with this ob-
servation, a PKA activator (Sp-cAMPS) impaired working memory in
aged rats, while low doses of a PKA inhibitor (Rp-cAMPS) had the op-
posite effect (Ramos et al., 2003). Interestingly, the beneficial effect of
PKA inhibition was more intense in animals with greater memory def-
icits due to aging. These observations suggest the importance of taking
into consideration age-related and region-specific biochemical differ-
ences when examining the cognitive enhancing properties of drugs that
Table 2
Summary of the different types of protein kinase A, their region-specific expression and function in the brain. PKA = protein kinase.
Group Regulatory domain subunits Expression CNS function
PKAI RIα and RIβ Neocortex, caudate-putamen, hypothalamus, thalamus, hippocampus Diverse, including memory
PKAII RIIα and RIIβ Medial habenula, hippocampus, thalamus Diverse, including memory
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act on the cAMP/PKA pathway.
5. Role of Epacs in modulating cAMP signaling
The discovery of Epacs brought a new perspective to the prevailing
view that PKA is the only downstream effector for cAMP signaling.
There are two isoforms of Epac, i.e. Epac1 and Epac2 (Epac2A and
Epac2B), produced by their two respective genes (Table 3). The C-
terminal catalytic region is the same for both Epacs and it is composed
of 3 domains: i) a Ras-exchange motif (REM) domain, ii) a Ras-asso-
ciation (RA) domain and iii) a GEF domain responsible for Epac ex-
change activity on Raf GTPases (De Rooij et al., 2000). The regulatory
N-terminus contains a dishevelled, Egl-10, pleckstrin (DEP) domain
responsible for membrane binding and a cyclic-nucleotide-binding
(CNB) domain that binds cAMP with high affinity (De Rooij et al.,
2000;, 1998). Although Epac1 and Epac2B have one CNB-B domain,
Epac2A has an additional CNB-A domain at the N-terminus. Despite
that difference, CNB-A binds cAMP with very low affinity in comparison
to CNB-B, and does not contribute significantly to Epacs’ regulation by
cAMP (Rehmann et al., 2003). Similarly to PKA, binding of cAMP to the
regulatory domain of Epacs leads to their activation. Subsequently,
Epacs activate the small GTPases Rap1 and Rap2 that represent their
main downstream effector (Kitayama et al., 1989). The tissue dis-
tribution of Epac1 and Epac2 differs since Epac1 appears to be widely
distributed, while Epac2 is mainly expressed in the brain and the
adrenal glands. Regarding their pattern of expression in the rat brain,
mRNA of Epac1 is abundantly expressed, but generally at low levels,
whereas the mRNA of Epac2 is highly expressed in certain regions in-
cluding cortex, hippocampus, habenula and cerebellum (Kawasaki
et al., 1998). At the subcellular level, Epacs are mainly localized in the
nuclear membrane and mitochondria, while during cell division they
are located to the mitotic spindle and centrosome (Qiao et al., 2002).
Through their effectors, Epacs can orchestrate several cellular
functions raging from gene transcription to cell proliferation and
apoptosis, and additionally regulate several intracellular pathways and
signaling processes. For example, downstream activation of ERK and
P13-kinase-dependent PKB/Akt pathway via Epacs, introduces an im-
portant link between Epac action and memory processes (Grandoch
et al., 2010). Both electrophysiological and behavioral studies suggest
the importance of Epacs in plasticity. Perfusion of mouse hippocampal
slices with the Epac agonist 8-(4-chlorophenylthio)-2′-O-methyl-cAMP
(8-pCPT) enhanced the maintenance of LTP induced by a weak tetanus,
without affecting the initial magnitude of potentiation. This effect was
shown to depend on ERK phosphorylation and protein synthesis, while
blockage of transcription and PKA activity did not abolish 8-pCPT-de-
pendent facilitation of LTP (Gelinas et al., 2008). These results suggest
that Epac activation initiates ERK signaling that subsequently promotes
local translation of a pre-existing pool of dendritic mRNAs (Gelinas
et al., 2008). Additionally, it has more recently been shown that Epac
plays an important facilitating role in cerebellar Purkinje cells during
LTP and motor learning (Gutierrez-Castellanos et al., 2017). It appears
that Epacs comprise a dual function in synaptic transmission since it
was shown that, except for the observed enhancement of synaptic
transmission, activation of Epacs could also induce LTD in hippocampal
slices. This function was shown to be dependent on activation of the
p38-mitogen activated protein (MAP) kinase pathway and on inter-
nalization of GluA2/3-containing AMPA receptors (Ster et al., 2009).
Considering that PKA was shown to facilitate LTP in the hippocampus
(Frey et al., 1993), the latter finding regarding Epac-dependent LTD
provides an additional pathway in the already established role of cAMP
signaling cascade in synaptic plasticity. Nevertheless, it still remains
unanswered which cellular components determine which pathway will
be activated in response to cAMP. Considering that PKA and Epacs have
the same affinity for cAMP in living cells, it was hypothesized that
subcellular compartmentalization or substrate availability determine
which downstream effector will be activated by cAMP (Ster et al.,
2009).
Consistent with the electrophysiological findings, the role of Epacs
in memory formation was supported by behavioral studies. Most im-
portantly, it was shown that Epacs participate in distinct stages of
memory formation. Intracerebroventricular (ICV) administration of 8-
pCPT 1 h after the fear conditioning paradigm improved mice perfor-
mance (Kelly et al., 2009). Similarly, intrahippocampal infusion of the
Epac agonist immediately after fear conditioning facilitated memory
formation and it was able to attenuate PKA antagonist-induced memory
impairments (Ma et al., 2009). Another study, that tried to gain more
insight into the distinct memory stages during which Epac activation
can facilitate memory, supports the idea that their intrahippocampal
activation facilitate contextual fear memory when it takes place at the
stage of retrieval, but not at the acquisition phase (Ostroveanu et al.,
2010). Additionally, it was shown that Epac2 is the responsible isoform
for the enhancing effects of Epac’s activation on memory retrieval, since
silencing of Epac2 via intrahippocampal injection of siRNA impaired
memory retrieval (Ostroveanu et al., 2010).
Although there is scarce of evidence, a few studies support a pro-
mising role of Epacs as a target in neurodegenerative diseases. For ex-
ample, in neuronal cell cultures, Epac1 can exhibit neuroprotective
action against the neuropathological features of Alzheimer’s disease
(AD). Specifically, activation of Epac1 after stimulation of the Gs-cou-
pled serotonin receptor could promote activation of the small GTPases
Rap1 and Rac1. This activation of the Epac1-Rap1-Rac1 signaling cas-
cade increased the cleavage of the amyloid precursor protein (APP) via
the α-secretase pathway (Maillet et al., 2003; Zaldua et al., 2007),
leading to the release of soluble APPα (sAPPα) at the extracellular
space (Robert et al., 2005). Importantly, it was shown that sAPPα has
promising cognitive enhancing and neuroprotective properties
(Allinson et al., 2003). These observations are particularly important
because they could extend our knowledge regarding AD pathology and
suggest novel targets for the treatment of the disease. Regarding the
role of Epac2 in neurodegenerative diseases, it is reported that Epac2
activation via 8-pCPT influences dendritic spine remodeling, and mu-
tations in the EPAC2 gene could contribute to brain disorders (Woolfrey
et al., 2009). Nevertheless, there is no further evidence supporting the
cognitive enhancing properties of Epac2 in AD.
6. Hyperpolarization-activated cyclic nucleotide–gated (HCN)
channels
Another class of cyclic nucleotide receptors are the hyperpolariza-
tion-activated cyclic nucleotide–gated (HCN) channels. HCN channels
are important membrane proteins that serve as nonselective voltage-
gated cation channels (Sartiani et al., 2017). As their name states, they
open at hyperpolarization potential and are regulated by cyclic nu-
cleotides (mainly cAMP). They conduct Na+ and K+ ions and are
mainly known for their pacemaking activity in cardiac cells, but are
also expressed in the brain where they can be found in neurons of the
hippocampus (He et al., 2014). The HCN family consists of four iso-
forms (HCN1–4), all of which have been found in mouse or human
brain tissue. HCN1 is highly expressed in the neocortex, hippocampus,
cerebellar cortex, brainstem, and spinal cord. HCN2 is widely dis-
tributed throughout the brain, but it is especially abundant in thalamic
Table 3
Summary of the different isoforms and splice variants of Epacs and their tissue-
specific expression. Epac = exchange protein directly activated by cAMP.
Isoforms Splice variant Expression
Epac1 Epac1 Widely distributed
Epac2 Epac2A +
Epac2B
Cortex, hippocampus, habenula, cerebellum,
adrenal glands
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and brainstem nuclei. The expression of HCN3 is limited and quite
scattered throughout the brain. HCN4 expression is strong in areas such
as the olfactory bulb and the thalamus, with a distribution pattern that
appears complementary to that of HCN1 (Sartiani et al., 2017).
The potential impact of HCN channels on plasticity mechanisms and
memory formation is supported by a limited number of studies. For
instance, in the dendritic compartment of hippocampal CA1 pyramidal
neurons, the effect exerted by HCN current limits the activation of
voltage-dependent Ca2+ entry, with important consequences on sy-
naptic excitability (Tsay et al., 2007). This way, LTP and memory
function are constrained by normal HCN function. Indeed, HCN1-KO
mice show improved hippocampal-dependent learning and memory
performance. In these mice, proximal synapses (CA3–CA1 contacts)
function normally, whereas they are potentiated at distal locations (EC
layer III–CA1 contacts), as predicted by stronger expression of HCN
channels in this compartment (Nolan et al., 2004). These effects were
accompanied by improvements in spatial memory performance. Simi-
larly, LTP was significantly increased in the perforant path of HCN2 KO
mice (Matt et al., 2011), while global KO of HCN3 had no significant
spatial learning deficits in comparison with control mice (Stieglitz et al.,
2018). Together, these early studies indicate therapeutic potential for
HCN channels as targets within the field of learning and memory.
7. Guanylate cyclases: regulation, tissue distribution and
participation in neuronal function
GCs are widely distributed signal transduction enzymes involved in
a variety of cellular processes including host defense reactions, cell
growth and cell proliferation (for a review see Evgenov et al., 2006). In
response to various cellular stimuli, they convert GTP into the second
messenger cGMP. In contrast to the transmembrane pGC that serves as a
receptor for atrial, B-type and C-type natriuretic peptides, sGC is a re-
ceptor for gaseous ligands, especially NO. As a result, sGC is especially
interesting in relation to brain neuroplasticity and memory formation.
It can associate with the plasma membrane through protein-protein
interactions in a constitutive or Ca2+-dependent manner (Agullo et al.,
2005; Burette et al., 2002; Russwurm et al., 2001; Zabel et al., 2002).
sGC is typically found as a heterodimer, consisting of a larger α-subunit
and a smaller haem-binding β-subunit, although it also exists as
homodimer (Zabel et al., 1999). Four human sGC subunits have been
identified: α1, α2, β1 and β2 of which the α1/β1 and α2/β1 dimers are
the most well-known (Table 4). The β-subunit contains an evolutiona-
rily conserved amino-terminal haem-binding domain, which is crucial
for the sensing of NO. Based on sequence homology with the crystal-
lized catalytic domains of AC, the carboxy-terminal catalytic domains of
both sGC subunits are assumed to be orientated in a head-to-tail
fashion. The catalytic domains of both subunits are required for the
formation of a catalytic active center (Evgenov et al., 2006; Mayer and
Koesling, 2001; Winger and Marletta, 2005).
The different human isoforms of sGC have been known for some
time, however little is known about their overall tissue distribution
(Budworth et al., 1999). Studies of rat brain have located sGC mRNA
predominantly in striatum, the olfactory system and layers II and III of
the cerebral cortex (Ding et al., 2004). More recently, expression pat-
terns in human brain and peripheral tissues have been determined. In
all the regions of the human brain investigated, pituitary gland and
placenta β1 mRNA expression is greater than α1 (Budworth et al.,
1999). Most of the other tissues studied showed greater α1 expression
compared to β1 especially in heart, prostate, small intestine and ap-
pendix. Some of the tissues displayed very low levels of expression of
both subunits including skeletal muscle, bladder, testis and peripheral
leukocytes. In contrast to the adult tissue, fetal brain showed similar
levels of α1 and β1. Both adult and fetal heart displayed more α1 than
β1. Fetal lung showed greater sGC expression than adult lung.
7.1. Role of sGCs in synaptic plasticity and memory
NO/sGC/cGMP signaling can be compromised either by reducing
the bioavailability of NO or by altering the redox state of sGC itself,
thereby making it unresponsive to endogenous NO and NO-releasing
drugs (Evgenov et al., 2006). This led to the development of two drug
classes to be able to overcome these obstacles: sGC stimulators (sti-
mulate sGC directly and enhance sensitivity of the reduced enzyme to
low levels of bioavailable NO) and sGC activators (activate the NO-
unresponsive, haem-oxidized or haem-free enzyme). However, sGC
stimulators and activators have mainly been investigated for their po-
tential as treatment of arterial and pulmonary hypertension, heart
failure, atherosclerosis, thrombosis, erectile dysfunction, renal fibrosis
and failure, and liver cirrhosis. Targeting sGC to enhance multiple as-
pects of memory processes in particular or neuroplasticity in general, is
a relatively new strategy in the field of sGC drug development, hence,
the limited availability of literature. To investigate the potential of
enhanced sGC signaling to improve memory function, studies use, next
to stimulators and activators, GC inhibitors as negative control. In this
respect, ODQ, a GC inhibitor (Garthwaite et al., 1995), has shown to
impair memory performance during the novel object recognition (NOR)
test in mice when administered 30 min before the retention trial (Akar
et al., 2014). Furthermore, ODQ impaired performance on the passive
avoidance test when administered 30 min before acquisition, but only
when combined with the NO precursor 7-nitroindazol (7-NI). By itself
neither drug had an effect. ODQ also significantly impaired olfactory
memory as reflected by the decreased ratio ‘percent cued food/percent
total food eaten’ in the social transmission of food preference test when
compared to the control group. ODQ has also shown to suppress LTP in
several studies (e.g. Arancio et al., 1995; Boulton et al., 1995; Chien
et al., 2003; Zhuo et al., 1994. Similarly, bilateral intrahippocampal
administration of the sGC inhibitor LY 83,583 caused full amnesia for
inhibitory avoidance when given immediately after training, but not 30
min post-training Bernabeu et al., 1997b).
Alternatively, the compound YC-1 which activates as well as sti-
mulates sGC, was shown to significantly decrease the acquisition la-
tency (1–4 days) of 24-month-old rats in the MWM when administered
daily for 2 weeks (Komsuoglu Celikyurt et al., 2014). Additionally, the
same 24-month-old rats showed a reduced time spent in the escape
platform's quadrant when compared to 4-month-old rats. YC-1 reversed
the reduction of the time spent in the escape platform's quadrant of the
24-month-old rats. YC-1 also reversed the diminished retention latency
in 24-month-old rats on the second day during the passive avoidance
task.
Additional support comes from Chien and colleagues, who also
showed that YC-1 shortened the escape latency in the MWM during the
test trial when injected 10 min before the first trial of each daily
Table 4
Summary of the different types of guanylate cyclases, their tissue-specific distribution and function in the brain. GC = guanylate cyclase, NO = nitric oxide.
Type Subunit Expression CNS function
Membrane-bound GC n.a. pineal gland, cerebellum, pituitary, olfactory epithelium receptor for atrial, B-type and C-type
natriuretic peptides
Soluble GC α1, α2, β1, β2 Heart, prostate, small intestine, appendix, Pituitary gland, placenta, hippocampus,
striatum, cerebral cortex and locus
receptor for gaseous ligands, especially NO
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training session, and increased and decreased the retention scores in the
passive and active avoidance task, respectively, when injected 10 min
before foot-shock training. Administration of YC-1 30 min after foot-
shock stimulation did not significantly affect retention scores in re-
sponse to the passive avoidance task. Administration of scopolamine, a
cholinergic muscarinic antagonist, markedly impaired memory acqui-
sition. Pretreatment with YC-1 inhibited the scopolamine-induced
learning deficit. The enhancement of learning behavior by YC-1 was
antagonized by ICV injection of the NOS inhibitor L-NAME and PKG
inhibitors KT5823 and Rp-8-Br-PET-cGMPS, indicating that the NO/
cGMP/PKG pathway is involved in the action of YC-1 (Chien et al.,
2008, 2005).
8. Role of PKG in synaptic plasticity and memory
PKG exists in two forms, the soluble PKGI and the membrane-bound
PKGII (Hofmann, 2005; Schlossmann and Hofmann, 2005). The two
PKG families (PKGI and PKGII) are encoded by different genes and they
are both homodimers consisting of two identical subunits, the C and the
R (Table 5). Each subunit has two binding sites for cGMP at the R do-
main, and allosteric binding of cGMP increases the catalytic kinase
activity of the enzyme 3- to 10- fold. Binding of cGMP to the R site does
not lead to its dissociation from the C site.Two isoforms of PKGI exist,
PKGIα and PKGIβ, which differ in their N-terminal domains. PKGIα is
activated at 10-fold lower cGMP concentrations compared to PKGIβ.
Both exhibit different physiological functions because they interact
with different substrates, vary in their regional and subcellular locali-
zation, and are expressed in different tissues. PKGIα is highly expressed
in cerebellum, dorsal root ganglia and lung, whereas PKGIβ is found
predominantly in hippocampus, olfactory bulb, smooth muscle and
platelets. PKGIβ expressed in the hippocampus is therefore believed to
be involved in LTP and spatial learning and memory. Interestingly,
PKGI KO mice showed no deficits in spatial and fear contextual
memory, while LTP impairment was present in old, but not young mice,
after a repetitive theta-burst stimulation protocol. Considering that LTP
induced by the implemented protocol requires protein synthesis, the
authors suggested that PKGI in hippocampus is involved in synthesis-
dependent L-LTP (Kleppisch et al., 2003).
Hippocampal PKGI signaling has shown to be mediated by vesicle
trafficking regulated by RhoA and vasodilator-stimulated phosphopro-
tein (VASP) (Wang et al., 2005b). PKGII is localized at the plasma
membrane and is expressed in the thalamus, septum, amygdala and
olfactory bulb, as well as intestinal mucosa, kidney and chondrocytes.
PKGII is much less investigated in relation to neuronal functions in-
cluding learning and memory, although PKGII KO mice have shown to
exhibit significant deficits in spatial learning in the MWM (Wincott
et al., 2013).
The critical role of PKG in especially the early stages of memory
function was suggested by studies using PKG activators and PKG in-
hibitors (which do not differentiate between PKGI and PKGII). First
support for a role of PKG in memory formation comes from the finding
that PKG inhibitors block LTP, and PKG activators facilitate LTP in
response to weak tetanic stimuli (e.g. Arancio et al., 2001, 1995;
Izquierdo et al., 2000; Zhuo et al., 1994). Also, rats submitted to
memory paradigms showed a significant increase in PKG activity in the
hippocampus (e.g. Bernabeu et al., 1997b). Interestingly, the increase
in PKG was only observed immediately after training, whereas no
changes were observed 30 min after training raising the idea that the
hippocampal PKG cascade is involved in the early stages of memory
formation. This is supported by the observation that the PKG activator
8-Br-cGMP showed a dose-dependent improvement in object recogni-
tion compared to saline condition, when administered bilaterally into
the hippocampus of rats immediately after the learning trial in the ORT
(Prickaerts et al., 2002a). Similarly, intrahippocampal infusions of the
PKG inhibitor KT5823 reversed an amyloid-β (Aβ)-induced increase in
escape latency and traveled distance in the MWM (Shariatpanahi et al.,
2016).
9. Regulation of the intracellular concentration of cyclic
nucleotides
The intracellular levels of cyclic nucleotides mainly depend on the
fine-tuning between their rate of production by AC and sGC and the rate
of elimination. The latter is mainly achieved by PDEs and by energy-
dependent transport of cyclic nucleotides to the extracellular space.
Additionally, the intracellular concentration of cyclic nucleotides is
regulated by their sequestration into functionally distinct compart-
ments within the cell.
9.1. Energy-dependent transport of cyclic nucleotides
The concept of active transport of cyclic nucleotides into the ex-
tracellular space has been mainly studied in other tissues rather than
the brain. Transport of cyclic nucleotides involves an organic anion
transport process that utilizes multidrug resistant proteins (MRPs).
Although there is scarce of evidence regarding the exact function of all
the members of the MRP family, it has been shown that cyclic nu-
cleotides can be substrates for MRP4, 5 and 8 (Chen et al., 2001; Guo
et al., 2003; Jedlitschky et al., 2000; Liqi and Theresa, 2002). Although
both cyclic nucleotides were shown to be substrates for these three MRP
subfamilies, a later study conducted with human erythrocytes sug-
gested that MRP5 mediates cGMP transport 20-times more efficiently
than transport for cAMP, indicating that cGMP is a more favorable
substrate for MRP5. Along the same lines, it was also shown that the
cGMP-specific PDE inhibitor, sildenafil, can block MRP5-mediated ex-
port of cGMP (Jedlitschky et al., 2000).
Regarding the expression of MRP1-6 in the adult human brain, it
was shown that only MRP1, 4, 5 are present in the brain, while the
other members of the family are not detectable in brain tissue (Nies
et al., 2004). Interestingly, MRP4 and 5 were both detected in astro-
cytes, while MRP5 was also present in pyramidal cells (Nies et al.,
2004). Although MRPs seem to participate in the regulation of cyclic
nucleotide concentration in neurons, this observation raises the ques-
tion of the purpose of an energy-dependent transport of cyclic nucleo-
tides into the extracellular space. A possible explanation could be that
this mechanism could serve as a cell-cell communication. For example,
in bacteria, cAMP at the extracellular space could bind to membrane
receptors and promote their differentiation (Janssens and Van Haastert,
1987). Nevertheless, there is not a mechanism described in mammals
that would explain this theory, especially considering that MRP-
Table 5
Summary of the different types of protein kinase G, their tissue/region-specific expression and function in the brain. PKG = protein kinase G.
Type Group PKG Isoform Expression CNS function
Soluble PKG PKGI PKGIα Cerebellum, dorsal root ganglia, lung Diverse, including memory
PKGIβ Hippocampus, olfactory bulb, smooth muscle, platelets Diverse, including memory
Membrane-bound PKG PKGII n.a. thalamus, septum, amygdala, olfactory bulb, intestinal mucosa, kidney,
chondrocytes
Scarce investigation into neuronal function
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mediated transport is unidirectional.
The most prominent explanation is that MRPs facilitate the extra-
cellular transport of cyclic nucleotides where they act as extracellular
messengers promoting an autocrine and paracrine mechanism. The
concept of extracellular cAMP and cGMP activity is not new (Stone and
John, 1990) and it is thought to contribute to plasticity and memory-
related functions of cyclic nucleotides (Ricciarelli and Fedele, 2018). In
particular, it was shown that upon extrusion to the extracellular space,
cAMP is converted to adenosine that subsequently mediates several
functions throughout the body and the brain via the adenosine re-
ceptors A1, A2A, A2B, and A3 (Godinho et al., 2015). More recent evi-
dence showed that externally applied cGMP could improve spatial
memory. Specifically, the study of Cabrera-Pastor et al. showed that
extracellular cGMP modulates glycine receptors leading to an increase
in intracellular Ca2+ and subsequently CaMKII activation (Cabrera-
Pastor et al., 2016).
9.2. Degradation of cyclic nucleotides by PDEs
Regulation of intracellular concentration of cyclic nucleotides
through degradation by PDEs has been extensively studied. By hydro-
lyzing cAMP and cGMP, PDEs play an important role in regulating
signal transduction mediated by cyclic nucleotides (Beavo, 1995). PDEs
are grouped into 11 families based on homology of the catalytic do-
main. Most of the families have more than one gene and each gene can
consist of several different splice variants and isoforms (Bender and
Beavo, 2006). In total, there are estimated to be over 100 specific
human PDEs, discretely localized to specific subcellular domains
(Houslay, 2010; Keravis and Lugnier, 2012). Additionally, the different
families of PDEs differ in their tissue distribution, properties and sub-
strate specificity with the latter constituting a fundamental distinction
between the PDE families. PDE1, PDE2, PDE3, PDE10, PDE11 have a
dual substrate specificity, hydrolyzing both cAMP and cGMP. PDE4,
PDE7 and PDE8 are cAMP-specific, while PDE5, PDE6 and PDE9 are
cGMP-specific (Table 6). Except for their role in hydrolysis, PDEs
mediate a more complex role in regulating and refining cyclic nucleo-
tide signaling in the brain. In this respect, it was shown that cyclic
nucleotides can regulate the activity of PDEs, providing a point of cross-
talk in which cAMP signaling could influence cGMP signaling and vice
versa (Fig. 1).
With the exception of PDE6 that is mainly found in the retina, all the
other families are expressed in several brain areas including the hip-
pocampus. Thereafter, several studies investigated the potential of PDE
inhibitors as cognitive enhancers. In the section below the 10 families
of PDEs are described and a review is provided on the current studies
regarding the role of PDE inhibitors in memory and memory-related
diseases.
9.2.1. Dual substrate specificity phosphodiesterases
PDE1 is a unique PDE family that is regulated by Ca2+ and acti-
vated by calmodulin. Three genes have been identified for the PDE1
family: PDE1A, PDE1B and PDE1C. All three are abundantly expressed
in the brain with the highest levels found in the striatum and moderate
levels in the cortex and the hippocampus (Cho et al., 2000; Yan et al.,
1994, 1996). The kinetic properties for the 3 isoenzymes differ with
PDE1A and PDE1B hydrolyzing cGMP with a Km value lower (3 μM)
than cAMP (50–100 μM), whereas PDE1C hydrolyzes both cAMP and
cGMP with similar Km value (1 μM) (Beavo and Houslay, 1990;
Loughney et al., 1996). Interestingly, the affinity of PDE1 for the Ca2+/
calmodulin complex is altered by phosphorylation. Specifically, phos-
phorylation of PDE1A1 and PDE1A2 by PKA (Sonnenburg et al., 1995),
and PDE1B1 by CaMKII (Hashimoto et al., 1989), decreases their affi-
nity for Ca2+/calmodulin, resulting in decreased activity for PDE1. Due
to its regulation mechanism, PDE1 constitutes an interesting point of
crosstalk and integration of intracellular pathways that are mediated by
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plasticity, the fact that phosphorylation by PKA decreases the activity of
PDE1A1 and PDE1A2 indicates that a signal that increases cAMP would
further prolong its action, imposing a paradigm of positive feedback
that is reversed after increased Ca2+ (Beavo, 1995). Additionally, it is
reported that cGMP can inhibit PDE1-induced hydrolysis of cAMP
(Loughney et al., 1996). Although PDE1 activity significantly con-
tributes to cGMP-mediated inhibition of cAMP hydrolysis in human
myocardium, this relationship is not yet determined in neuronal cells.
Regarding the action of PDE1 inhibition in the brain, a recent study
from Snyder et al. showed that acute treatment with the selective PDE1
inhibitor ITI-214 can improve several stages of mnemonic process in
heathy rats after acute treatment (Snyder et al., 2016).
PDE2 is highly expressed in the brain and alternative splicing of the
same gene results in 3 isoforms: PDE2A1, PDE2A2 and PDE2A3
(Rosman et al., 1997; Sonnenburg et al., 1991; Yang et al., 1994). In the
rat brain, PDE2 mRNA can be found in the hippocampus, cortex,
amygdala, cerebellum, striatum and hypothalamus (Stephenson et al.,
2012; Van Staveren et al., 2003). The different isoforms of PDE2 differ
in their N-terminal sequence introducing differences in their hydro-
phobicity and subsequently cellular distribution. Additionally, the N-
terminus has two cGMP-binding domains, GAF-A and GAF-B, partici-
pating in dimerization and binding of cGMP, respectively (Martinez
et al., 2002b). Although, PDE2 has a dual substrate specificity, hydro-
lyzing both cAMP and cGMP with similar catalytic properties (Km= 30
μM for cAMP and 10 μM for cAMP), cGMP seems to be a preferred
allosteric modulator for PDE2, causing cGMP to be more effective in
activating PDE2 (Beavo et al., 2006). Specifically, binding of cGMP to
one of the GAF domains induces an allosteric modification that lowers
the Km for cAMP and promotes up to a 30-fold increase in cAMP hy-
drolysis (Martinez et al., 2002a; Michie et al., 1996). Because of its
function, PDE2 is part of a negative feedback mechanism that facilitates
crosstalk between cGMP and cAMP pathways, implicating important
physiological functions. For example, in the brain, signals that elevate
intracellular cGMP levels promote PDE2-mediated cAMP hydrolysis,
restoring basal levels of cyclic nucleotides (Bender and Beavo, 2006).
Particularly, at the presynaptic terminal of the CA1 area in the rat
hippocampus, PDE2A can modulate cAMP levels in response to acti-
vation by cGMP, indicating a modulatory role of PDE2A in short-term
synaptic plasticity (Fernández‐Fernández et al., 2015). The latter was
also highlighted in the study of Boyken et al. in which PDE2A expres-
sion appeared very high in the docked fraction of synaptosomes, sug-
gesting an important role of PDE2A in neurotransmitter release from
the presynaptic terminal (Boyken et al., 2013).
The expression of PDE2 in brain areas that are involved in memory
and cognition rendered it a promising target for the development of
cognitive-enhancing drugs. The first available PDE2 inhibitor BAY
60–7550 was shown to enhance memory acquisition and consolidation
in healthy mice and rats in the ORT when administered before and after
the learning trial, respectively (Boess et al., 2004; Rutten et al., 2007).
These memory enhancing effects of BAY 60–7550 are inhibited after co-
administration of NOS or PKG inhibitors, indicating that the effect of
BAY 60–7550 on memory seems to be mediated primarily through ac-
tivation of the sGC/cGMP/PKG cascade (Domek-Łopacińska and
Strosznajder, 2008). Additionally, it was shown that BAY 60–7550
could improve memory performance in a mouse model for AD, without
combating the Aβ pathology of the disease (Sierksma et al., 2013).
PDE3 is encoded by two genes, PDE3A and PDE3B with three
(PDE3A1, PDE3A2,PDE3A3) (Wechsler et al., 2002) and one splice
variants (PDE3B1) (Beavo et al., 2006), respectively. In the rat brain,
PDE3A mRNA has been found in the cortex, cerebellum and brain stem
(Bolger et al., 1994), while PDE3B mRNA is mainly found in peripheral
tissues with prominent expression in the cardiovascular system
(Reinhardt et al., 1995). PDE3 hydrolyzes both cAMP and cGMP in a
competitive manner, with same catalytic properties for both nucleo-
tides (Km = 0.2 μM for cAMP and Km = 0.1 μM for cGMP). However,
the velocity for cAMP hydrolysis is 4- to 10-fold higher than for cGMP
and the substrate affinity for cGMP is higher (Beavo, 1995). Therefore,
increased production of cGMP through activation of sGC, could inhibit
PDE3-mediated hydrolysis of cAMP, rendering it a cGMP-inhibited
PDE.
The different variants are distinguished by the different lengths of
the N-terminal domain. The difference in length of the N-terminus be-
tween the variants determines their subcellular localization and their
regulation by kinases. The longest variant, PDE3A1, has two N-terminal
hydrophobic associated regions (NHR1 and NHR2). It also contains one
phosphorylation site for protein kinase B (PKB) and two phosphoryla-
tion sites for PKA. The latter was shown to activate PDE3A1 (Wechsler
et al., 2002), downregulating cAMP signaling through negative feed-
back. PDE3A2 lacks the NHR1 domain along with the PKB phosphor-
ylation site, but contains NHR2 and the two phosphorylation sites for
PKA. The shortest variant, PDE3A3, lacks all the above domains and
phosphorylation sites (Zaccolo and Movsesian, 2007).
There are several drugs that can inhibit both isoenzymes equally
including cilostazol, cilostamide, enoximone and milrinone.
Considering the role of PDE3 inhibitors in memory and cognition en-
hancement, most of the supportive evidence comes from studies con-
ducted with cilostazol. Behavioral studies showed that the neuropro-
tective effect of cilostazol against Aβ-induced memory impairments
can, at least in part, be attributed to reduction of oxidative stress and
prevention of Aβ accumulation (Hiramatsu et al., 2010; Park et al.,
2011). A study conducted with a transgenic mouse strain that exhibits
accelerating aging showed that administration of cilostazol for 3
months could have a neuroprotective effect that is reflected in the
molecular level by increased p-CREB in the hippocampus and improved
integrity of the blood-brain barrier (BBB) (Yanai et al., 2017). Finally, it
was shown that treatment with cilostazol for one month could protect
against tau pathology and cognitive decline in the rTg4510 mouse line
via increasing proteasome activity (Schaler and Myeku, 2018).
PDE10 and PDE11 are two distinct families that were characterized
more recently. Regarding PDE10, the entire family is encoded by one
gene, PDE10A, and alternative splicing generates 18 splice variants
(PDE10A1-18) (Strick et al., 2006). In rat brain, PDE10A mRNA is
highly expressed in the striatum, but it is also found in the hippo-
campus, cortex and cerebellum (54, 56, 57). PDE10A hydrolyzes both
cyclic nucleotides with a significantly higher affinity for cAMP (Km =
0.20 μM) than for cGMP (Km = 1 μM). Because the maximum velocity
for hydrolyzing cGMP is 5-fold higher than the one for cAMP, PDE10A
hydrolysis of cGMP seems to be inhibited by cAMP (Fujishige et al.,
1999; Soderling et al., 1999). Therefore, PDE10A may function as a
cAMP-inhibited phosphodiesterase and as a result, stimuli that elevate
cAMP could subsequently increase cGMP levels. This function is op-
posite from the one described for the PDE3 family (Bender and Beavo,
2006). As with PDE2, PDE10A has 2 GAF domains in the N-terminus. in
vitro studies have shown that the GAF domains of PDE10A have very
low affinity for cGMP (Soderling et al., 1999), and it is considered
highly impossible for a cell to reach such high concentrations of cGMP
in order to bind to each one of the GAF domains. Nevertheless, the
possibility that a certain regulation could increase the affinity of GAF
domains for cGMP cannot be abolished. Accordingly, it was recently
shown in vitro that PDE10A allosterically binds cAMP in one of the GAF
domains (Gross-Langenhoff et al., 2006). Regarding its function in the
hippocampus, it was reported that mRNA levels of specific PDE10A
splice variants are increased after induction of LTP, providing a reg-
ulatory mechanism to dampen LTP-induced elevated levels of cGMP
(O’Connor et al., 2004).
PDE10A1 and PDE10A2 represent the major PDE10A variants in
humans (Fujishige et al., 1999, 2000). A notable difference between the
two isoforms is that only PDE10A2 has a PKA phosphorylation site at
the N-terminal domain (Kotera et al., 1999b) that alters its localization
from Golgi apparatus to cytosol (Kotera et al., 2004). That change in
PDE10A2 distribution may represent a negative feedback in response to
elevated cytosolic levels of cAMP (Kotera et al., 2004). In concordance
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with the abundant expression of PDE10A in the striatum, development
of PDE10 inhibitors currently aims at the treatment of motor disorders.
In addition, PDE10 inhibition was shown to have antipsychotic poten-
tial and improved cognitive symptoms in animal models of schizo-
phrenia, providing a new therapeutic approach for the disorder (Grauer
et al., 2009; Megens et al., 2014; Menniti et al., 2007; Schmidt et al.,
2008), though clinical trials with schizophrenia patients did not results
in any positive effects.
PDE11 is the newest member of the PDE family which has similar
affinities for both nucleotides (Km = 1–2 μM for cGMP and Km = 2–3
μM for cAMP), and catalyzes both substrates with similar velocity. Four
splice variants of the PDE11A gene have been identified (PDE11A1-
PDE11A4) that differ in the amino-terminal sequence. PDE11A2 and
PDE11A3 have one complete and one incomplete GAF domain in the N-
terminus (Beavo et al., 2006), whereas PDE11A4 has two complete GAF
domains with phosphorylation sites for PKA and PKG (Yuasa et al.,
2000). Expression of PDE11 in the brain is relatively low, but it is
profoundly distributed in the ventral hippocampus, CA1, subiculum
and the amygdalohippocampal area (Kelly et al., 2010). Nevertheless,
there is a recent study showing that PDE11 KO mice exhibit particular
behavioral and biochemical changes observed in psychiatric disorders
including hyperactivity and deficits in tests related to social behavior
(Kelly et al., 2010). The involvement of PDE11 in social memory came
from a later study in which PDE11 KO mice exhibited normal STM, but
not LTM, for social recognition, while non-social odor recognition
memory was unaffected. The impaired consolidation of social memory
was shown to be associated with decreased protein synthesis in the
ventral hippocampus (Hegde et al., 2016a, b). Recently, the first potent
PDE11 inhibitors have been identified in a high-throughput screen in a
yeast-based assay, paving the way for the development of selective
PDE11 inhibitors (Ceyhan et al., 2012).
9.2.2. cAMP-specific phosphodiesterases
This category of PDEs contains three members that are all highly
expressed in the brain; PDE4, PDE7 and PDE8. Among them, PDE4 has
a prominent position since it is the best characterized and inhibition of
PDE4 constitutes a potent method for upregulating the cAMP/PKA
(Km<10 μM) cascade. Additionally, PDE4 enzymes are distinguished
from other PDEs due to their specific inhibition by rolipram. PDE4 is
encoded by four different genes (PDE4A-PDE4D), and more than 25
different human isoforms have been described (Beavo et al., 2006).
PDE4A, PDE4B and PDE4D are highly expressed in the hippocampus,
striatum, thalamus, cortex and cerebellum, while the expression of
PDE4C in the brain is relatively low (Lakics et al., 2010). PDE4A and
PDE4B constitute the majority of membrane-bound PDE4, and PDE4D
the majority of soluble PDE4 in the brain (McPhee et al., 1995).
PDE4 enzymes have two unique highly conservatory domains at the
N-terminal domain; upstream conserved region 1 and 2 (UCR1 and
UCR2). The presence or absence of these domains divides PDE4 iso-
forms into three groups: the long, the short and the super short variants.
Specifically, the long variants have both the UCR1 and UCR2 domains,
the short variants have a complete UCR2 domain and the super-short
variants have a truncated UCR2 domain (Bolger et al., 1993). UCR1 has
a phosphorylation site for PKA and upon phosphorylation diminishes
PKA’s affinity to UCR2, and subsequently promotes PDE4 activation
(Beard et al., 2000). Furthermore, PKA phosphorylation alters the
sensitivity of PDE4 towards inhibition by rolipram (HOFFMANN et al.,
1998), probably due to conformational changes in the catalytic region
(Beard et al., 2000). The activity of PDE4 is also regulated by ERK
phosphorylation in the catalytic domain. ERK phosphorylation pro-
motes activation of the short PDE4 variants and inhibits the long PDE4
variants, while the ERK phosphorylation motif is absent in the super
short variants (Baillie et al., 2000). Therefore, phosphorylation by ERK
and PKA is particularly interesting in the case of long isoforms and is
considered to regulate cAMP signaling. Activation of ERK can inhibit
the activity of the enzyme, elevating cAMP levels. Subsequently, PKA
activation reliefs ERK-mediated inhibition and reactivates catalytic
activity of PDE4, lowering cAMP to its basic levels (Hoffmann et al.,
1999). Although it is not shown yet in neuronal cells, CaMKII can also
modulate PDE4D activity in cardiac myocytes. At both basal state and
after stimulation of the cAMP pathway, CaMKII activates PDE4D via
phosphorylation providing an additional mechanism, besides PKA-
mediated PDE4 activation, for controlling intracellular cAMP levels
(Mika et al., 2015).
Crystallographic studies revealed multiple conformations for PDE4
isoenzymes that could also alter the catalytic activity of the enzyme
(Burgin et al., 2010). In one conformation, the α-helix-UCR2 from one
monomer folds over and interacts with the catalytic site of the other
monomer, resulting in>50 % inhibition of the enzyme. The UCR2
autoinhibition is removed by PKA phosphorylation of UCR1. Con-
versely, phosphorylation by ERK stabilizes the UCR2-autoinhibition
state (Houslay and Adams, 2010). The sequence of the α-helix is the
same for all the isoforms with the exception of a single amino acid that
differentiates PDE4D from the other PDE4 isoforms. In fact, this poly-
morphism has been utilized for the development of isoform-selective
inhibitors (Burgin et al., 2010; Houslay and Adams, 2010). In a dif-
ferent PDE4 conformation, the helix of the C-terminus, which is called
Control Region 3 (CR3), interacts with the catalytic site of the same
monomer, causing complete autoinhibition of the enzyme. As with
UCR2, a unique polymorphism in the CR3 helix distinguishes PDE4B
and PDE4D isoforms and has been exploited for the development of
selective PDE4B inhibitors with promising anti-inflammatory action
(Ahmad et al., 2015; Fox et al., 2014).
Since PDE4 is highly expressed in the hippocampus, PDE4 inhibitors
have been extensively studied as cognitive enhancers. In addition to
pro-cognitive action, rolipram was shown to reverse plasticity impair-
ments and cognitive decline in several transgenic AD mouse models
(Barad et al., 1998; Costa et al., 2007; Gong et al., 2004; Rutten et al.,
2006). The cognitive enhancing effect of rolipram was related to the
attenuation of decreased CREB phosphorylation, as observed in the
disease (Yamamoto-Sasaki et al., 1999). In the study of Vitolo et al. it
was suggested that the Aβ peptide prevents AC activation leading to
lower intracellular levels of cAMP that shifts the equilibrium towards
the inactive form of PKA. Subsequently, treatment with rolipram re-
stores the balance, promoting PKA dissociation and CREB phosphor-
ylation (Vitolo et al., 2002). Except for restoring CREB phosphorylation,
it was shown that activation of cAMP/PKA can enhance proteasome
activity and subsequently promote tau clearance (Myeku et al., 2016).
Similarly, a newly synthetized PDE4 inhibitor FFPM was also shown to
ameliorate cognitive decline in APP/PS1 mouse model by promoting
cAMP/PKA/p-CREB/BDNF pathway and reducing the levels of in-
flammatory factors (Guo et al., 2017). Another possible mechanism by
which PDE4 inhibition could be neuroprotective against AD pathology
is via activation of the small heat-shock protein 20 (Hsp20). In parti-
cular, Hsp20 binds directly to PDE4 within a region of the catalytic
domain, remaining in a non-phosphorylated state (Sin et al., 2011).
Disruption of Hsp20-PDE4 complex for example via PDE4 inhibition
promotes phosphorylation of Hsp20 by PKA/PKG at Ser16. Subse-
quently, phosphorylated Hsp20 interacts with Aβ preventing its ag-
gregation into toxic oligomers (Cameron et al., 2014). Although the
latter finding suggests that PDE4 inhibition could protect against Aβ
pathology, there is no animal study at the moment showing that PDE4
inhibition could combat amyloid deposition.
Despite the promising preclinical findings, clinical studies with
PDE4 inhibitors have been hampered due to dose-limiting emetic ef-
fects. In this respect, recent studies indicate the importance of devel-
oping more selective PDE4 inhibitors in order to dissociate the pro-
cognitive action from the emetic effect. The newly described PDE4 in-
hibitors GEBR-7b and GEBR-32a enhanced memory performance in
healthy mice and an AD mouse model with doses being at least 100
times lower than the one inducing emesis (Bruno et al., 2011; Ricciarelli
et al., 2017). Of note, it was shown that the cognitive enhancing effect
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of GEBR-7b does not involve changes in Aβ pathology (Bruno et al.,
2011). Roflumilast, a PDE4 inhibitor that is already clinically approved
for the treatment of chronic obstructive pulmonary disease (COPD)
(Hatzelmann et al., 2010), was shown to improve cognition in both
healthy adult rodents as well as healthy adult volunteers at non-emetic
doses (Van Duinen et al., 2018; Vanmierlo et al., 2016). Finally, de-
velopment of allosteric modulators of PDE4 gained more interest the
past few years. Accordingly, the allosteric modulator D159687 was
shown to exert pro-cognitive action in cynomolgus macaques, at a dose
that is 60 times lower than the one eliciting emesis (Burgin et al., 2010).
When it comes to treatment with PDE4 inhibitors or other drugs that
upregulate cAMP signaling, an important aspect is the transcriptional
regulation of the PDE4 family by cAMP. Several studies have shown
that chronic treatment with antidepressants that stimulate the cAMP
signaling pathway, could upregulate expression of PDE4A and PDE4B
in the rat frontal cortex without affecting PDE4D levels (Takahashi
et al., 1999; Ye et al., 1997). Later studies that examined in more detail
the expression of the different variants of PDE4A, PDE4B and PDE4D
isoforms after chronic administration of fluoxetine showed a more
complex regulation of their expression (Dlaboga et al., 2006). Repeated
treatment with fluoxetine increased PDE4D1/PDE4D5 in the mouse
cerebral cortex, while it decreased expression of all the PDE4B variants
tested. Additionally, PDE4D3 expression was increased in both the
cerebral cortex and the hippocampus (Dlaboga et al., 2006). Further
studies showed that fluoxetine administration reduced PDE4D3 ex-
pression in the cingulate cortex, while PDE4D4 expression was in-
creased in the frontal and frontoparietal cortex. Moreover, expression of
PDE4D1 and PDE4D5 was decreased in several areas of the hippo-
campus (Miró et al., 2002). These studies indicate that the earlier re-
sults, showing unaltered levels of PDE4D expression after fluoxetine
treatment, most likely represent the net result of opposing changes in
different PDE4D splice variants. In cortical cell cultures, stimulation of
cAMP by dibutyryl-cAMP promotes the expression of the short variants
PDE4B2 and PDE4D1/PDE4D2, while PDE4A levels remain unaltered.
This finding is particularly interesting since these variants were almost
undetectable at basal conditions, and their expression was increased in
a cAMP-activated state (D’sa et al., 2002). Additionally, repeated
treatment with rolipram differentially altered the expression of the
PDE4 variants in the cerebral cortex and the hippocampus. PDE4D3
expression was increased in both brain areas examined. Nevertheless,
chronic treatment with rolipram decreased PDE4A1/PDE4A5 levels in
the hippocampus, while PDE4B1/PDE4B2/PDE4B3 expression was in-
creased in the cerebral cortex. Taken together, all the above mentioned
studies indicate that transcription of PDE4 variants in the brain is
controlled by cAMP signaling in a isoenzyme and brain-specific manner
(Sasaki et al., 2004).
The PDE7 family includes two genes, PDE7A and PDE7B, and hy-
drolyses cAMP with high affinity (Km<0.2 μM). Alternative splicing
gives rise to three splice variants for PDE7A (PDE7A1-3) (Glavas et al.,
2001; Han et al., 1997) and PDE7B (PDE7B1-3) (Sasaki et al., 2000) in
rats. However, in humans only one variant has been described for
PDE7B. Although the N-terminal domain does not contain regulatory
sites, it interacts directly with the catalytic domain of PKA, inhibiting
its action (Han et al., 2006). The latter provides an alternative way in
which PDE7 could downregulate the cAMP/PKA signaling pathway.
Due to the high expression of PDE7A1 and PDE7A3 in a variety of
human immune cells, specific inhibition of these variants seems a
promising approach for preventing chronic inflammation (Glavas et al.,
2001; Smith et al., 2003). Except for peripheral tissues, PDE7 is highly
expressed in the brain and both PDE7A and PDE7B were found in the
hippocampus, cortex and striatum in the rat brain (Johansson et al.,
2012; Miro et al., 2001). PDE7B1 is ubiquitously expressed in the
striatum and it was shown to possess a prominent role in regulating
dopamine-mediated cAMP signaling in striatal neurons (Sasaki et al.,
2004). Elevation of cAMP/PKA levels in the striatum promotes tran-
scriptional activation of PDE7B1 providing a negative feedback that
eventually down-regulates intracellular cAMP levels (Sasaki et al.,
2004). Therefore, development of specific inhibitors for the PDE7B1
isoform could be an alternative strategy for the treatment of diseases
related to loss of dopaminergic signaling. Although there are a few
potent PDE7 inhibitors, there is a scarce of evidence regarding their
effect on memory. A newly described compound VP1.15 that inhibits
both PDE7 and glycogen synthase kinase 3 (GSK-3) showed pro-cog-
nitive action in healthy mice (Lipina et al., 2013). Additionally, chronic
treatment with the PDE7 inhibitor S14 in AD mice ameliorated memory
impairment and reduced pathological hallmarks of the disease, in-
cluding Aβ deposition and tau phosphorylation (Perez-Gonzalez et al.,
2013). Clearance of Aβ deposits was mediated by astroglial phagocy-
tosis, outlining the protective potential of PDE7 inhibition against
neuroinflammation.
The PDE8 family contains two genes, PDE8A and PDE8B, and shows
the highest catalytic rates for cAMP (Km∼0.8 μM) among all PDEs.
PDE8A mRNA is expressed in a variety of peripheral tissues and with
regard to its brain expression, it can be found in the substantia nigra,
thalamus and to a lesser extend in the hippocampus and cortex (Kruse
et al., 2011). PDE8B mRNA is mainly expressed in the brain and more
precisely in the hippocampus, cortex, striatum and midbrain
(Kobayashi et al., 2003). The N-terminal region contains REC (receiver)
and PAS (Per, Arnst and Sim) regulatory domains that participate in a
communication system and in protein interaction in prokaryotes. Their
specific function in vertebrates remains unknown. Similarly to other
PDE families, upon increased cAMP levels, PKA phosphorylation in-
creases the catalytic activity of the enzyme, providing a negative
feedback mechanism (Brown et al., 2012). Considering the high dis-
tribution of PDE8B in the hippocampus, it is considered a promising
target for the treatment of memory-related disorders. To our current
knowledge, one selective PDE8B inhibitor has been identified, but pre-
clinical development was halted due to peripheral side effects in dogs
(DeNinno et al., 2012).
9.2.3. cGMP-specific phosphodiesterases
This category of PDEs comprises PDE5, PDE6 and PDE9, with PDE5
representing the most well-studied family. PDE5 is encoded by a single
gene with different promoters resulting in three variants of the gene,
i.e. PDE5A1, PDE5A2 and PDE5A3. The three variants differ at their N-
terminus and tissue localization. Although PDE5 has two GAF domains
(GAF-A and GAF-B) at the N-terminus, cGMP binds only to GAF-A.
Activation of the enzyme requires a well-orchestrated series of events
that is initiated by elevated intracellular cGMP levels. Subsequently,
cGMP interacts with the catalytic domain, facilitating binding of cGMP
to the GAF-A domain (Francis et al., 1980; Thomas et al., 1990). The
latter promotes phosphorylation of specific serine residual that in-
creases by 10-fold the affinity of the enzyme for cGMP and additionally
promotes its catalytic activity (Corbin et al., 2000; Francis et al., 2002).
The main kinase that mediates this phosphorylation is PKG. Never-
theless, when cGMP reaches high levels, PKA can also phosphorylate
the enzyme, prolonging its activation. This mechanism provides a ne-
gative feedback loop, ensuring that intracellular cGMP concentration
will not exceed the appropriate levels (Corbin et al., 2000). Ad-
ditionally, both cyclic nucleotides were shown to promote transcrip-
tional regulation of PDE5A via regulatory elements in the promoter of
the gene. In rat cell cultures, a cAMP analog stimulated transcription of
PDE5A2 and in lesser extend PDE5A1, probably via association with
CRE (Kotera et al., 1999a). Additionally, cGMP and cAMP were shown
to facilitate PDE5A1 transcription via the AP-2 and Sp-1 sequences in
the promoter of the gene (Lin et al., 2001).
Similar to PDE3 and PDE4 inhibitors, PDE5 inhibitors are well-
known for their vascular effects. More specifically, PDE5 inhibition
causes relaxation of smooth muscles in blood vessels, hence its im-
portance for the treatment of erectile dysfunction. Sildenafil, vardenafil
and tadalafil are examples of FDA approved PDE5 inhibitors for the
treatment of erectile dysfunction. Because of their vasodilatory
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properties, sildenafil and tadalafil are also FDA approved for the
treatment of hypertension of the pulmonary artery. Nevertheless, there
is an extensive body of evidence indicating their promising cognitive
enhancing properties in healthy, aged and AD animal models. Several
studies showed that sildenafil improves memory formation in healthy
mice, rats and cynomolgus macaque, either when given before or im-
mediately after the mnemonic test (Prickaerts et al., 2005, 2002b;
Rutten et al., 2008, 2005). Additionally, sildenafil could compensate
against memory impairments in AD and aged mice. In addition to re-
stored CREB phosphorylation, treatment with sildenafil also resulted in
reduction of pathological hallmarks related to AD and aging. For ex-
ample, chronic treatment with sildenafil reduced Aβ deposition in APP/
PS1 mice (Puzzo et al., 2009), and normalized the amyloidogenic APP
cleavage pathway in aged mice (Puzzo et al., 2014). Accordingly, a
recent study showed that as with rolipram, sildenafil could activate
Hsp20 in cell cultures, preventing aggregation of toxic Aβ fibrils
(Cameron et al., 2017).
Despite the cerebrovascular effect of PDE inhibitor, animal studies
showed that the cognitive enhancing properties of sildenafil cannot be
attributed to increased cerebral blood flow (Rutten et al., 2009) and
metabolism in the brain, but are mainly related to underlying me-
chanisms of plasticity (Puzzo et al., 2009; Zhang et al., 2013). Never-
theless, four clinical studies have tested the effects of PDE5 inhibition
on memory in healthy volunteers and none of these studies proved a
therapeutic benefit on cognitive function (Prickaerts et al., 2017).
Cognitive ceiling effects may have been a limiting factor in these stu-
dies, since they were conducted in healthy volunteers. Another point of
concern regarding the commercially available PDE5 inhibitors is their
lack of selectivity. For example, sildenafil also inhibits PDE6 that is
expressed in the retina and therefore chronic administration could
cause visual disturbances. The past few years considerable efforts have
been made for the development of more selective PDE5 inhibitors with
optimal kinetic properties. In this respect, the newly synthetized com-
pounds 7a and 6c represent optimized versions of the existing PDE5
inhibitors with higher selectivity for the enzyme and increased BBB
permeability (Fiorito et al., 2013, 2017). Additionally, both inhibitors
were shown to exert neuroprotective mechanism against synaptic and
memory deficits in APP/PS1 mice.
PDE9 family is encoded by one gene, PDE9A, and hydrolyses cGMP
with the highest affinity (Km∼0.17 μM) among the cGMP-specific
PDEs, supporting the idea that it is the main regulator of cGMP sig-
naling in the brain (Van Staveren et al., 2002). Despite the identifica-
tion of one gene, complex processing of its mRNA results in twenty-one
splice variants (Rentero et al., 2003). Unlike the other PDEs, the N-
terminal domain of the PDE9A isoenzyme does not contain GAF do-
mains or any other regulatory regions. Additionally, the sequence of the
catalytic domain appears to be unique among the other PDEs. The latter
results in unresponsiveness of PDE9A to common PDE inhibitors (Fisher
et al., 1998; Soderling et al., 1998). PDE9A mRNA is expressed in
several peripheral tissues. Regarding PDE9A mRNA expression in the
brain, studies with rodents showed diverse patterns of distribution of its
transcripts, with high levels in the hippocampus, cortex, olfactory bulb,
striatum, thalamus, amygdala and the highest expression in the cere-
bellum (Van Staveren et al., 2002, 2003). At the cellular level, PDE9A is
mainly localized in neuronal cell bodies and dendrites (Kleiman et al.,
2012). Additionally, PDE9A exhibits a distinct pattern of subcellular
distribution that is region-specific. For example, in the cerebellum,
PDE9A is evenly distributed in the plasma and nucleus, while in the
hippocampus it is mainly found in the nucleus (Patel et al., 2018).
So far, three potent PDE9 inhibitors, BAY 73–6691, PF-04447943
and BI 409306, were shown to promote synaptic plasticity and enhance
memory performance in healthy rodents. Additionally, these drugs
were able to reverse scopolamine-induced memory impairments in both
mice and rats, indicating a promising role for AD (Hutson et al., 2011;
Van Der Staay et al., 2008; Vardigan et al., 2011). In that respect, BAY
73–6691 was shown to protect against synaptic deficits induced by
Aβ42 oligomers and improve memory performance in an AD transgenic
mouse model (Kroker et al., 2014). Additionally, it was shown in vitro
that PDE9 inhibition by either BAY 73–6691 or PF-04447943 could
protect against Aβ-induced cytotoxicity (Cameron et al., 2017). The
same study showed that PDE9 inhibition offered a higher level of
neuroprotection and with an earlier onset in comparison to rolipram
and sildenafil treatment (Cameron et al., 2017). Notably, newly syn-
thesized PDE9 inhibitors were able to prevent Aβ aggregation into toxic
fibrils and this neuroprotective function was attributed to their anti-
oxidant ability (Zhang et al., 2018) or metal-chelating capacity (Su
et al., 2016). Nevertheless, the nuclear distribution of PDE9A suggests
that PDE9 inhibition could not compensate for deficits in sGC signaling
(Kelly, 2017) that are encountered in both AD patients and models of
AD pathology (Baltrons et al., 2002; Bonkale et al., 1995).
10. Signal compartmentalization of cyclic nucleotides
The concept of signal compartmentalization has emerged as a need
to understand the complex and specific spatiotemporal signaling pro-
cesses in response to extracellular stimuli. Since cAMP participates in a
plethora of cellular pathways, its signal sequestration is essential for
proper regulation. Discrete compartments of cAMP gradients are
shaped by A-kinase anchoring proteins (AKAPs) that act as a scaffold,
binding several components of the cAMP signaling cascade, including
ACs, PDE4, PKA, Epacs and phosphatases. The presence of several
components and regulators of the cAMP signaling cascade in the same
complex results into feedback loops in which initial activation of ACs
and elevation of cAMP levels, activates PKA that eventually potentiates
cAMP degradation via PDEs. The AKAP family is comprised of over 50
members (Tasken and Aandahl, 2004; Tröger et al., 2012). Regulation
of PKA compartmentalization into discrete intracellular compartments
is mainly determined by the subunit composition of PKA. The two R
isoforms, RI and RII, and subsequently PKAI and PKAII are differen-
tially expressed in tissues and show distinct cellular distribution. Their
interaction with AKAPs mainly contributes to the anchoring of the
different PKA classes into specific subcellular structures. Although the
majority of AKAPs show preference for the PKAII class (Skroblin et al.,
2010), there have been identified AKAPs that are specific for both PKA
classes. Considering that the AKAPs anchor together PKA molecules
with their substrates or effectors, sequestration of cAMP/PKA signaling
provides an advantageous mechanism ensuring fast intracellular re-
sponses to extracellular stimuli (for a review, see (Cheng et al., 2008)).
AKAP5, also known as AKAP150 in rodents (orthologue of human
AKAP79 and bovine AKAP75), is highly expressed in neural cells and is
able to anchor PKAII in the postsynaptic terminal of neurons (Carr
et al., 1992; Sarkar et al., 1984). Except for the unique PKA binding
domain, AKAP5 also contains three sequences at the N-terminal that
facilitate targeting of the anchoring protein to the neuronal plasma
membrane. In the mouse brain, AKAP5 is mainly distributed in the
hippocampus, amygdala and cortex, suggesting a pivotal role in the
processes of learning and memory (Glantz et al., 1992; Moita et al.,
2002; Ostroveanu et al., 2007; Ulfig and Setzer, 1999). Regarding its
subcellular localization, AKAP5 is found in the dendrites and more
specifically in the postsynaptic density (PSD) of dendritic spines, where
it regulates their structure and function (Robertson et al., 2009). Te-
thering of AKAP5 to PSD is achieved via interaction of structural
components including PIP2, F-actin, cadherins (Gomez et al., 2002;
Gorski et al., 2005) and membrane-associated guanylate kinase
(MAGUK) (Colledge et al., 2000; Robertson et al., 2009). In the PSD,
AKAP5 interacts with a plethora of signaling molecules including PKC
(Faux et al., 1999), calmodulin (Faux and Scott, 1997), CaN (Faux and
Scott, 1997), as well as receptors and ion channels including AC5, AC6
(Bauman et al., 2006), L-type calcium channel (Hall et al., 2007;
Oliveria et al., 2007), potassium channel (Dart and Leyland, 2001; Tao
et al., 2005) and β-adrenergic receptor (Fraser et al., 2000). Ad-
ditionally, AKAP5 binds indirectly to AMPA receptors via the MAGUK
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scaffolding protein SAP-97, and to NMDA receptors via PSD-95
(Colledge et al., 2000), orchestrating glutamatergic neuronal trans-
mission.
Except for the above interaction with structural and signaling mo-
lecules, AKAP5 was shown to mediate a well-orchestrated modulation
of cAMP pools in neuronal cells via interaction with PDE4. The most
well-studied paradigm represents the PKA/AKAP5-mediated regulation
of the β2-adrenergic receptor (β2-AR) via PDE4D5 (Houslay, 2010;
Lynch et al., 2005). Specifically, β2-AR is coupled to both Gs and Gi
proteins and phosphorylation of the receptor by PKA switches its cou-
pling from Gs to Gi (Daaka et al., 1997). Activation of the β2-AR by its
agonist promotes activation of AC via Gs that subsequently elevates
cAMP intracellular concentration. When this concentration reaches the
threshold for promoting activation of AKAP5-anchored PKA, the latter
phosphorylates β2-AR and switches its coupling to Gi. The dissociated
Gβγ subunit initiates a cascade of signaling molecules that lead to ERK
activation (Daaka et al., 1997). Recruitment of the βarrestin-bound
PDE4D5 into the β2-AR signaling complex provides a negative feedback
by lowering cAMP concentration and attenuating the ability of AKAP5-
anchored PKA to phosphorylate β2-AR. In this signaling cascade, dis-
ruption of PKA-AKAP5 tethering prevents ERK activation, even when
PDE4D5 was knocked-down (Lynch et al., 2005), outlining the im-
portance of sequestration of PKA and PDE4D5 in regulating cAMP
concentration.
There is a growing body of evidence indicating that the AKAP5
signalosome is important for mediating neuronal signaling and facil-
itating mnemonic processes. An example of this action represents the
regulation of AMPA receptor trafficking in the synapse. Most of the
hippocampal synapses contain GluA1/2 and GluA2/3 AMPA receptors
(Kessels et al., 2009). Activation of cAMP signaling increases channel
open probability of the GluA3-containing AMPA receptors (Gutierrez-
Castellanos et al., 2017; Renner et al., 2017), as well as, trafficking of
GluA1-containing AMPA receptors to extrasynaptic sites (Banke et al.,
2000; Esteban et al., 2003; He et al., 2009; Man et al., 2007; Oh et al.,
2006; Yang et al., 2008). In response to NMDA receptor activation and
PKC phosphorylation, extrasynaptic AMPA receptors move to the sy-
napse facilitating LTP induction (Guire et al., 2008; Opazo et al., 2010).
Subsequently, dephosphorylation by CaN induces removal of the sy-
naptic GluA1-AMPA receptors via endocytosis during LTD (Ashby et al.,
2004; Lee et al., 1998, 2009). Anchoring of PKC and CaN by AKAP5
(Guo et al., 2015) facilitates activation, rapid endocytosis and exocy-
tosis of AMPA receptors in response to a signal.
As mentioned above, the brain distribution of AKAP5 suggests an
eminent role in memory formation. In this respect, induction of LTP in
vivo caused upregulation of AKAP150 mRNA during L-LTP (Tunquist
et al., 2008). Additionally, it was shown that AKAP5 null neurons ex-
hibit altered synaptic plasticity and impaired LTD, due to exclusion of
PKA and CaN from the dendritic spines (Genin et al., 2003). In ac-
cordance with the important role of LTD in memory formation
(Collingridge et al., 2010), AKAP KO mice also exhibit impairments in
memory retention (Tunquist et al., 2008). Additionally, both LTP and
LTD were abolished in a mouse strain (D36) carrying a truncated ver-
sion of AKAP5 that prevents binding of PKA (Lu et al., 2007, 2011).
These results indicate that D36 mice exhibit a more severe electro-
physiological impairment in comparison to AKAP KO mice. This ob-
servation was also confirmed in the study of Weisenhaus et al. that
additionally examined whether the reported electrophysiological defi-
cits are extended to the behavioral level (Weisenhaus et al., 2010). In
their study, D36 mice appear to have more pronounced impairments in
reversal learning in an operant conditioning paradigm for food reward
in comparison to AKAP KO mice. The differences between the two
strains indicate the importance of interaction between PKA and AKAP5
in controlling synaptic transmission.
Accordingly, several studies demonstrated that anchoring of PKA to
AKAP5 is critical for maintaining compartmentalized cAMP signaling
that subsequently coordinates learning and memory (Poppinga et al.,
2014). In that respect, most of the animal studies indicate the im-
portance of PKA-AKAP5 interaction utilizing the fear conditioning
paradigm. In the study of Moita et al. the st-Ht31 peptide that competes
for the binding site of PKA in the AKAP5 (Dodge and Scott, 2000), was
infused in the lateral amygdala of mice and resulted in impaired con-
solidation of fear memory (Moita et al., 2002). A later study extended
these findings showing that AKAP5 is upregulated in the hippocampus
of mice during exposure to a novel context, but also at the late con-
solidation period of fear conditioning memory (Nijholt et al., 2007).
Along the same lines, disruption of PKA-AKAP5 anchoring in the hip-
pocampus via the st-Ht31 peptide or the more specific superAKAP-IS
peptide prevented late-consolidation, but not acquisition and retrieval
of fear memories (Nijholt et al., 2008). Finally, KO of AKAP5 was ac-
companied with spatial memory retention deficits evaluated with the
MWM test in mice (Tunquist et al., 2008).
11. Temporal distinction in cyclic nucleotide signaling: time
windows of action
The molecular mechanism underlying different mnemonic stages is
a matter of investigation for several years and it still remains elusive.
Interestingly, several experimental lines indicate that cyclic nucleotides
participate in distinct time windows of memory processes. Specifically,
the sGC/cGMP/PKG signaling pathway is involved in the early con-
solidation phase, while AC/cAMP/PKA signaling is implicated in the
late consolidation stage (Izquierdo et al., 2002). An important aspect of
this temporal distinction is whether cyclic nucleotides act in parallel or
sequential to activate CREB. In other words, does cGMP/PKG signaling
at the early phase depend on cAMP/PKA signaling at the late phase of
consolidation or do the two signaling cascades act independently
during memory formation?
Early work with LTP experiments showed that cGMP/PKG is in-
volved in L-LTP by promoting CREB phosphorylation and Ca2+ release
from ryanodine stores (Lu and Hawkins, 2002; Lu et al., 1999). These
experiments support the notion that the cGMP/PKG pathway acts in-
dependently of the cAMP/PKA pathway to promote CREB phosphor-
ylation and eventually protein synthesis required for long-term plasti-
city. The parallel action of the two pathways was further underpinned
by studies conducted in honeybees showing that an externally applied
cGMP analog could synergistically activate PKA at the presence of na-
nomolar concentrations of cAMP (Leboulle and Müller, 2004). Never-
theless, there are studies showing that the two pathways are converging
in order to produce long-term plasticity. A study conducted in crickets
showed that activation of the NO/cGMP cascade precedes activation of
the cAMP signaling pathway for the formation of long-term memory. In
fact, it is suggested that NO/cGMP stimulates cAMP activation via
CNGC and calmodulin (Matsumoto et al., 2006). Based on the model
that the authors proposed, cGMP promotes activation of CNGC leading
to increased influx of Ca2+ that in turn activates calmodulin. Finally,
the Ca2+/calmodulin complex could directly activate ACs, providing
the link between the two cyclic nucleotide cascades. Of note, in the
cricket study, the cGMP analogs were applied externally. A follow-up
study showed that cGMP produced in physiological conditions after a
learning paradigm could not activate PKA even in the presence of low
levels of cAMP (Matsumoto et al., 2009). The authors suggested that the
contradictory findings indicate that cGMP production and PKA activa-
tion occur in different subcellular compartments in the same or in
different neurons. Therefore, in physiological conditions PKA is in-
accessible to cGMP (Matsumoto et al., 2009).
A later study from Bollen et al. in which they targeted cGMP/PKG
and cAMP/PKA pathways during specific time windows of plasticity
and memory formation, underscored the temporal dissociation of the
signaling cascades and, additionally, the cGMP-mediated modulation of
the cAMP pathway (Bollen et al., 2014). The electrophysiological study
showed that activation of the cGMP/PKG pathway before or 10 min
after a weak tetanus-induction protocol could convert E-LTP to L-LTP,
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suggesting that both acquisition and early consolidation are cGMP/PKG
dependent. The same observation was possible for the cAMP/PKA
pathway when it was activated either before or 90 min after the in-
duction protocol suggesting that the cAMP/PKA pathway participates
in acquisition and late consolidation processes. At the behavioral level,
activation of the cGMP/PKG pathway at the early consolidation time
window or the cAMP/PKA pathway at the late consolidation time
window could extend STM into LTM, as tested with rats in the ORT. The
existence of defined time windows in the action of cyclic nucleotides
was outlined from a later study showing that the pro-cognitive effect of
upregulating the cGMP/PKG cascade is apparent when it takes place
within 45 min after training in the ORT. However, elevation of cAMP/
PKA cascade is only effective when it occurs between 3 and 5.5 h after
training in this test (Akkerman et al., 2016). Additionally, the previous
study of Bollen et al. showed that early activation of cGMP/PKG re-
quires intact cAMP/PKA signaling at the late phase in order to promote
L-LTP and LTM. In both electrophysiological and behavioral studies, the
plasticity and memory enhancing properties of cGMP/PKG activation
were abolished when PKA was blocked at the late phase of LTP or
memory formation. On the contrary, PKG inhibition at the early phase
of plasticity and memory did not affect the pro-cognitive effect of
cAMP/PKA pathway activation at the late phase. These findings suggest
that activation of cGMP/PKG at the early phase of plasticity or con-
solidation requires cAMP/PKA signaling at the late phase for main-
taining L-LTP and LTM (Bollen et al., 2014). Importantly, a temporal
distinction in the action of cyclic nucleotides can be only made for the
consolidation phase, since upregulation of either cGMP/PKG or cAMP/
PKA at the acquisition phase has pro-cognitive effects (Fig. 2).
Considering the various experimental procedures and the different
complexities of the organisms that have been employed in these studies,
it is difficult to draw a conclusion regarding the temporal relationship
between cGMP/PKG and cAMP/PKA pathways. Nevertheless, the evi-
dence so far points out that, at least in mammals, these two cyclic
nucleotide signaling cascades act in parallel during the acquisition
phase, while at the consolidation phase, activation of cGMP/PKG and
cAMP/PKA is sequential. This observation raises several questions re-
garding the mechanistic relationship between the two cyclic nucleotide
signaling cascades. For example, by which mechanisms the cGMP/PKG
cascade promotes activation of the cAMP/PKA cascade? Considering
that PKG inhibition at the early phase of memory consolidation did not
affect the pro-cognitive effect of cAMP/PKA at the late consolidation
phase, it is unlikely that PKG acts directly on the cAMP/PKA cascade.
Nevertheless, it is possible that cGMP promotes cAMP/PKA activation
via another downstream effector, like cGMP-regulated ion channels.
Additionally, if PKA inhibition at the early phase of LTP and memory
consolidation does not affect the pro-cognitive action of cGMP/PKG
upregulation, what is the relevance of the immediate peak in PKA ac-
tivity at the very early phase of a memory task, as was reported in
previous studies (Bernabeu et al., 1997a; Mizuno et al., 2002; Vázquez
et al., 2000)? A possible explanation is that PKG and PKA share a
common downstream effector at this very early phase and therefore
concomitant inhibition of PKA and activation of PKG maintain an intact
underlying mechanism. Both PKG and PKA phosphorylate the GluA1
subunit of the AMPA receptor at the same serine residue (S845),
Fig. 2. Schematic representation of the different phases of plasticity and memory. Synaptic plasticity can be divided in the sub-types of short-term potentiation
(STP) that typically last less than 1 h and long term potentiation (LTP) that could last up to several hours. LTP can be further divided in early LTP (E-LTP or LTP1) and
late LTP (L-LTP). L-LTP is divided into LTP-2 and LTP-3. It is suggested that these sub-types of plasticity represent different memory stages, with E-LTP/LTP-1 being
equivalent to short-term memory (STM), LTP2 being related to intermediate memory (IM) and LTP3 underlying long-term memory (LTM). Transformation of one
memory stage into another is mediated by the mnemonic process of consolidation. Acquisition is the phase in which sensory information enters the brain. Encoding
represents the initial phase of memory formation that is active during acquisition and shortly after, when the information is not present anymore. Consolidation
characterizes stabilization of the initial labile memories. It is suggested that the transition of STM to IM and from IM to LTM is mediated by early and late
consolidation, respectively. The different stages of plasticity and memory formation are governed by distinct molecular cascades. Both cyclic monophosphate
adenosine (cAMP)/ protein kinase A (PKA) signaling and cyclic monophosphate guanosine (cGMP)/ protein kinase G (PKG) signaling are involved during the
acquisition phase. Additionally, early consolidation is dependent on activation of the cGMP/PKG signaling pathway, whereas late consolidation relies on activation of
the cAMP/PKA cascade. The y-axis represents the magnitude of synaptic plasticity described as field-excitatory postsynaptic potential (fEPSP).
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promoting its trafficking into the membrane (Serulle et al., 2007). Thus,
it is plausible that this common mechanism could explain the above
finding regarding the role of cyclic nucleotides at the very early phase
of plasticity and memory formation. Such a common mechanism has
been suggested to relate to the memory processes of encoding, which
are active during acquisition and continue during a short period after
acquisition, i.e. into the actual consolidation window (Akkerman et al.,
2015). Finally, what is the therapeutic relevance of the temporal dis-
tinction in the function of cyclic nucleotides? Considering that activa-
tion of the cGMP/PKG and the cAMP/PKA cascade via, for example,
specific PDE inhibitors induces unwanted side effects, combining
cGMP- and cAMP-selective PDE inhibitors at low sub-efficacious doses
could be a possible alternative treatment (Bollen et al., 2015). In that
case, the pro-cognitive effects of upregulating the cGMP/PKG and
cAMP/PKA cascade will be maintained, while the unwanted side effects
are circumvented.
12. New techniques in detecting, measuring and modulating
cyclic nucleotide signaling
So far, we presented data of the last decades indicating the com-
plexity of cyclic nucleotide signaling and the plethora of molecules that
orchestrate cAMP and cGMP dynamics and their subcellular distribu-
tion. Better understanding of cyclic nucleotide signaling imposed the
need for new ways to measure levels of cAMP and cGMP in cells.
Biochemical techniques including radio- and immuno-assays can give a
relative estimation of the amount of cAMP or cGMP in cell lysates.
Nevertheless, these techniques require a large amount of cells or tissue,
lack spatiotemporal resolution and cannot provide evidence for the
real-time changes in cAMP/cGMP gradients in living cells. The devel-
opment of optical biosensors based on Förster resonance energy transfer
(FRET) significantly improved our ability to measure and monitor
cyclic nucleotide signaling (Sprenger and Nikolaev, 2013).
12.1. Application of FRET imaging for detecting cAMP signaling
The first biosensors for detecting cAMP intracellular levels utilized
the dissociation of the C and R regulatory subunits of PKA upon cAMP
binding. The first cAMP biosensor named “FlCRhR” comprised a
fluorescein-tagged C subunit and a rhodamine-labeled R subunit in
which binding of cAMP to the R subunit caused dissociation of the
subunits and reduction in FRET emission (Adams et al., 1991). A few
years later, Zaccolo et al. developed a genetically encoded cAMP bio-
sensor in which the R or the C subunit of PKA was fused with a fluor-
escent probe (Zaccolo et al., 2000). Although utilization of FlCRhR
provided information about the spatial distribution of cAMP/PKA
during stimulation of sensory neurons in Aplysia (Bacskai et al., 1993),
and the PKA-based biosensor was proven useful in unraveling cAMP
signaling dynamics and compartmentalization in rat cardiac myocytes
(Zaccolo and Pozzan, 2002), their application was restricted due to
technical difficulties. For example, transfection of the whole ho-
loenzyme in the case of FlCRhR was not feasible in neurons, while PKA
biosensors required transfection of both plasmids and equal subunit
distribution in the cytosol.
The discovery of Epacs as additional downstream effectors of cAMP
signaling, led to the development of singled-chained Epac-based bio-
sensors. Both Epac1 and Epac2 were fused with cyan-fluorescent pro-
tein (CFP) at the N-terminus and yellow-fluorescent protein (YFP) at the
C-terminus to generate the first Epac1 and Epac2 biosensors. Binding of
cAMP to the biosensor introduces conformational changes reducing
yellow to cyan emission and therefore decreasing FRET (DiPilato et al.,
2004; Nikolaev et al., 2004; Ponsioen et al., 2004). Fusion of Epac1-
camps to the N-terminal domain of the different PKA subunits led to
PKA-RI- and PKA-RII-specific FRET biosensors (Wachten et al., 2010).
As it was shown before, PKA-RI and PKA-RII are tethered to distinct
cellular compartments via AKAPs. These compartments generate
spatially distinct modulation of intracellular signaling cascades in re-
sponse to extracellular stimuli (Wachten et al., 2010). Utilization of
PKA-RI and PKA-RII biosensors in rat myocytes revealed a micro-
domain-specific regulation of cAMP levels mediated via different PDEs
(Stangherlin et al., 2011). In these cells, simulation of the β-AR gen-
erates a spatially restricted pool of cAMP that mainly activates PKA-RII
and to lesser extend PKA-RI. Increased production of cGMP via stimu-
lation of sGC promotes activation of PDE2 that is in close proximity to
the PKA-RII pool and inhibition of PDE3 that resides close to PKA-RI,
reversing the PKA-defined cAMP gradient (Stangherlin et al., 2011).
Additionally, Epac2-camps tagged to AC8 (Epac2AC8D416N) helped to
identify distinct pools of cAMP microdomains associated with AC ac-
tivity in pituitary cells (Wachten et al., 2010). Worth mentioning is that
Calebiro et al. generated a transgenic mouse line (GAG-Epac1-camps)
that expresses an Epac1 biosensor ubiquitously allowing examination of
cAMP signaling in a more physiological context (Calebiro et al., 2009).
The most well-known Epac-based probes are called ICUE (indicator
of cAMP using Epac), and so far there have been developed three ver-
sions of the construct (ICUE1-3) with progressively improved properties
(DiPilato et al., 2004; Liu et al., 2012; Marley et al., 2013). ICUE1
constructs that were modified to be expressed in the plasma membrane,
mitochondria and the nucleus revealed the dynamics and the propa-
gation of cAMP signaling in the subcellular compartments in response
to adrenergic stimulation (DiPilato et al., 2004). ICUE3 probes targeted
to the nucleus provided a first indication of the role of the nuclear PKA
holoenzyme, showing that it is activated in response to sAC (Sample
et al., 2012). Additionally, utilization of ICUE3 probe revealed a novel
role of the actin binding protein coronin 1 in modulating synaptic
plasticity and neurobehavioral processes via potentiation of the cAMP/
PKA pathway (Jayachandran et al., 2014).
An alternative approach to detect cAMP signaling is via the A-kinase
activity reporter (AKAR). This family of biosensors contains a PKA
substrate sequence and a phospho-binding domain sandwiched be-
tween 2 fluorescent proteins (eCFP and YFP/Venus). Increased PKA
activity leads to phosphorylation of PKA substrate and subsequent
binding to the phospho-domain increasing FRET. The study of Gervasi
et al. in which they used AKAR2, showed the differential amplitude and
time course of PKA signal integration from membrane to the nucleus in
response to AC or GPCR stimulation (Gervasi et al., 2007). Additionally,
utilization of AKAR2 provided evidence showing that anchoring of PKA,
AC5 and AC6 by AKAP150/79, facilitates a negative feedback me-
chanism that reduces cAMP production (Bauman et al., 2006). Along
similar lines, a study from Schott et al. in which they targeted AKAR3 to
the plasma membrane or the cytosol, reported that gravin (or AKAP12)
impacts subcellular PKA activity levels through the spatial targeting of
PKA in response to Ca2+ elevation. The above results support the hy-
pothesis that gravin mediates crosstalk between Ca2+ and PKA-de-
pendent signaling pathways (Schott et al., 2016). A modified version of
AKAR4 that was targeted at lipid raft and non-raft regions of the plasma
membrane gave first insight into the compartmentalization of PKA ac-
tivity in the different microdomains in the membrane (Depry et al.,
2011). Additionally, Epac1, Epac2 and AKAR2 biosensors revealed
differential regulation of the cAMP/PKA pathway in response to β-AR
stimulation in two different compartments of the cell; the bulk cytosol
of the cell bodies and the submembrane domain of the thin dendrites
(Castro et al., 2010). Specifically, the amplitude of the cAMP/PKA re-
sponse in the cell soma was weaker in comparison to the thin dendrites,
supporting modeling predictions showing that the surface to volume
ratio affects cAMP dynamics (Neves et al., 2008). Accordingly, bio-
sensor imaging in mouse brain slices showed that cAMP/PKA signaling
differs between striatal and cortical neurons, with the first exhibiting
faster and longer-lasting responses to stimuli that elevate cAMP/PKA
pathway (Castro et al., 2013). This difference could be attributed to
several parameters including enhanced PDE4 activity in the cortex and
stronger AC activation in the striatum (Castro et al., 2013).
Recently, imaging of PKA activity in brain tissue has been
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established by the development of PKA-based biosensors that are
compatible for 2-photon microscopy. Fluorescence Lifetime Imaging
Microscopy (FLIM) represents a revolutionary approach of FRET ima-
ging that promises to overcome limitations that did not allow FRET
imaging in thick brain tissue (van Munster and Gadella, 2005; Wallrabe
and Periasamy, 2005). For instance, a study from Chen et al. reported
that a FLIM-AKAR biosensor could detect changes in PKA activity in the
soma and the dendrites of CA1 neurons in response to GPCR activation
and AC stimulation (Chen et al., 2014a). Importantly, implementation
of two-photon fluorescence lifetime imaging microscopy (2pFLIM)
coupled to an optimized AKAR variant (tAKARα sensor) unable re-
searches to track bidirectional PKA activities in individual neurons in
awake mice and reveal neuromodulatory PKA events that were asso-
ciated with wakefulness, pharmacological manipulation, and locomo-
tion (Ma et al., 2018).
12.2. Application of FRET imaging for detecting cGMP signaling
The development of cGMP FRET probes was based on the utilization
of a cyclic nucleotide binding domain derived from PKG or cGMP-
specific PDEs fused within two fluorophores forming a FRET pair. A
challenge in the development of cGMP probes was achieving high
specificity for the probes, because the levels of cGMP in a cell are lower
than the levels of cAMP. The first PKG-based biosensor, called Cygnet-1
(cyclic GMP indicator using energy transfer), was comprised by a
truncated version of PKGIα at the N-terminus fused between CFP and
YFP, while Cygnet-2 was the catalytically inactive variant of Cygnet-1
(Honda et al., 2001). In both probes, binding of cGMP led to decreased
FRET. The development of Cygnet biosensors contributes to our
knowledge regarding the dynamics and the regulation of cGMP sig-
naling in various cell types (Cawley et al., 2007; Mongillo et al., 2006;
Takimoto et al., 2005). In the brain, the use of Cygnet in thalamic
neurons showed that although they express PDE1, 2, 9 and 10, basal
cGMP concentration is mainly regulated by PDE2 activity (Hepp et al.,
2007). Additionally, Cygnet was used in combination with an Epac-
based sensor (EPAC-SH150) to disentangle the role of cyclic nucleotide
signaling in medium spiny neurons (MSNs) in the striatum (Polito et al.,
2013). The study showed that cGMP signaling could reduce cAMP
signaling through activation of PDE2 in the MSNs (Polito et al., 2013).
Despite the fact that Cygnet biosensors enable the monitoring of
cGMP levels and extend our knowledge regarding cGMP signaling, they
exhibited low dynamic range and temporal resolution. Nikolaev et al.
developed three shorter cGMP biosensors containing a single cGMP-
binding domain from PKGIα (cGES-GKIB) or the GAF domain from
PDE2 (cGES-DE2) or PDE5 (cGES-DE5) (Nikolaev et al., 2006). Binding
of cGMP decreases the FRET signal in case of the PKGIα-based bio-
sensor, while the FRET signal increases in the case of PDE-based bio-
sensors. Replacement of CFP/YFP in the cGES-DE5 sensor by a red
(Dimer2) and green (T-Sapphire) fluorescent protein allowed simulta-
neous imaging of two FRET sensors (i.e. cAMP and cGMP biosensors) in
the same cell (Niino et al., 2009). Surprisingly, the replacement of the
fluorescent pair increased its affinity for cGMP by 40-fold, making it the
most promising sensor for measuring real-time cGMP concentration in
living cells (Niino et al., 2009). A few years later, a new series of cGMP
biosensors was developed, i.e. cGi-500, cGi-3000, cGi-6000, with EC50
of 500 nM, 0.3 μM and 0.6 μM, respectively. These biosensors exhibit
high selectivity for cGMP and a better dynamic range than the previous
cGMP biosensors (Russwurm et al., 2007).
In an effort to increase the sensitivity for cGMP biosensors, Nausch
et al. developed non-FRET biosensors named FlincGs (fluorescent in-
dicators for cGMP). These biosensors (α-FlincG, β-FlincG, and δ-FlincG)
contain a truncated cGMP binding domain from PKGIα or PKGIβ
flagged with a circularly-permuted enhanced GFP (cpEGFP), and
binding of cGMP increases the fluorescence emitted by cpEGFP (Nausch
et al., 2008). Finally, a recent cGMP biosensor was constructed con-
taining the GAF-A domain of PDE5 fused between a blue fluorescent
donor and a dark fluorescent acceptor. The development of this bio-
sensor permitted triple parameter fluorescent imaging utilizing the blue
fluorescent cGMP biosensor, a CFP/YFP cAMP sensor and a red fluor-
escent probe for Ca2+ in a single cell (Niino et al., 2010).
Worth mentioning is that FRET sensors have been developed for
detecting levels of cyclic nucleotides in close vicinity of PDEs.
Specifically, Herget et al. fused Epac1-camps or cGES-GE2 to the N-
terminus of PDE3A, PDE4A1 or PDE5A (Herget et al., 2008). These
sensors allow detection of differences in cAMP and cGMP gradients
around PDEs and contribute to a better understanding of PDE activity in
cellular processes and in the compartmentalization of cyclic nucleotide
signaling. Additionally, these sensors were used for evaluating the ef-
fect of selective PDE inhibitors in the local pools of cAMP gradients and
compare their different pharmacokinetic properties (Herget et al.,
2008).
12.3. Modulation of cAMP and cGMP signaling via optogenetics
Despite these techniques for detecting cyclic nucleotide signaling in
living cells, the need to actively modulate neurons with high temporal
resolution remained. The expanding toolbox in neuroscience techniques
gave researchers the opportunity to modulate neurons via light. The
technique of optogenetics is based on the presence of photosensory
domains in light-sensing organisms. The initial optogenetic studies in
the nervous system used the light-gated ion channels channelrhodopsin
(ChR) and halorhodopsin (HR) to gain more insight into molecular
cascades and networks that are activated during neuronal plasticity
(Boyden et al., 2005; Zhang et al., 2007). Coupling of a photoreceptor
domain to different effector domains of cAMP or cGMP permits opto-
genetic manipulation of cyclic nucleotide signaling. Specifically, ab-
sorbance of light from the chromophore in the synthetic light-re-
sponsive system induces a conformational change that activates the
effector domain. The responsiveness of the system in the different light
spectra depends on the photoreceptor domain. Common chromophores
used in the development of optogenetics tools are the light-oxygen-
voltage-sensing (LOV) domain and the blue light utilizing flavin (BLUF)
domain.
The first photoactivated adenylate cyclase (PAC), named euPAC,
was identified in Euglena gracilis in which it was serving a role in
photoavoidance. This AC has a heterotetrameric structure consisting of
two PACα and PACβ that are activated by blue light and four catalytic
domains homologous to group III ACs (Iseki et al., 2002). The func-
tional expression of PACα and PACβ was verified in different systems
including Xenopus laevis oocytes, HEK293 cells, Aplysia and Drosophila
melanogaster (Nagahama et al., 2007; Schröder-Lang et al., 2007). The
large size and high basal activity in the dark after in vivo expression
prevented the wide application of euPAC in other organisms. Another
PAC, named BlaC, was constructed by Gomelsky and colleagues. The
construct was containing the blaC gene encoding a group III AC isolated
from Beggiatoa sp. and one BLUF domain, reducing the size significantly
(Ryu et al., 2010). Around the same time the group of Hegemann va-
lidated the efficacy of the same protein, which they named bPAC (Stierl
et al., 2010). In Escherichia coli and Xenopus oocytes, bPAC showed low
cyclase activity in darkness that is increased by 300-fold in the light.
Additionally, the applicability of bPAC was validated in rat cortical
neurons (Stierl et al., 2010), Drosophila nervous system (Efetova et al.,
2012; Stierl et al., 2010) and zebrafish (De Marco et al., 2013, 2016;
Gutierrez-Triana et al., 2015). More recently a blue light-regulated AC
was identified in Microcoleus chthonoplastes, named mPAC. This enzyme
contains a photoreceptive LOV domain and exhibits higher constitutive
activity in comparison to euPAC and BlaC/bPAC, but also higher ac-
tivity after blue light irradiation (Chen et al., 2014b; Raffelberg et al.,
2013). Although the promising dynamic range, extensive use of these
PACs was restricted due to disadvantages in the use of blue light in-
cluding low tissue penetration and photooxidative damage (Hockberger
et al., 1999). The first synthetic PAC that is activated in the near-
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infrared window (NIRW) was engineered by the group of Gomelsky
(Ryu et al., 2014). The Ilac construct was containing a photosensory
module from the Rhodobacter sphaeroides bacteriophytochrome DGC,
BphG1 and a typre III AC domain from the Nostoc sp. CyaB1 protein.
The effectiveness of Ilac was tested in cholinergic neurons of Cae-
norhabditis elegans in which exposure to red light altered the locomotor
behavior of the animal indicating elevation in cAMP/PKA signaling
(Ryu et al., 2014). Importantly, generation of NIRW-activated ACs
provides the opportunity of combinatory imaging techniques for de-
tecting or manipulating cyclic nucleotide signaling.
The first photoactivated GC was constructed by multiple mutations
in the Beggiatoa BlaC. The triple mutant, designated BlgC, was shown to
exhibit GC activity in vitro and irradiation with blue light resulted in
significant increase in cGMP production in vivo (Ryu et al., 2010). The
first natural light-activated GC was identified in fungus Blastocladiella
emersonii by the group of Gomes (Avelar et al., 2015; Scheib et al.,
2015). The BeGC1, as it was named by the Gomes group, consists of
rhodopsin fused to a GC catalytic domain and is activated by green
light. The efficacy of the enzyme was confirmed in in vitro and in vivo
assays including HEK293 T cells, Xenopus oocytes, muscle cells of
Caenorhabditis elegans, mammalian ovary cells and cortical neurons
(Scheib et al., 2015). Additionally, Gomelsky’s group engineered a
NIRW-activated construct for the production of cGMP (Ryu and
Gomelsky, 2014). The chimeric construct was comprised of a bacter-
iophytochrome c-di-GMP synthase (diguanylate cyclase, DGC) origi-
nating from the Rhodobacter sphaeroides BphG1 protein and a con-
stitutive c-di-GMP-specific PDE, YhjH from E. coli. DGC is not expressed
in higher eukaryotes and could allow orthogonal regulation of c-di-GMP
signaling in mammals (Ryu and Gomelsky, 2014).
A different angle in the attempt to manipulate the cyclic nucleotide
signal constituted the engineering of light-activated PDEs (LAPD). The
first photoactivated PDE was comprised of the photosensor module of
Deinococcus radiodurans bacterial phytochrome and the effector module
of the human phosphodiesterase 2A (Gasser et al., 2014). The photo-
activated construct has dual substrate specificity and illumination with
red-light could enhance the hydrolysis of cGMP and cAMP by 6-and 4-
fold, respectively. Additionally, exposure of LAPD to far-red light could
decrease its activity. The efficacy of LAPD in increasing hydrolysis of
cyclic nucleotides was established in eukaryotic cell cultures and zeb-
rafish embryos (Gasser et al., 2014). Although LAPD appears promising
for studies in living organisms, the dual specificity of the enzyme does
not allow distinction between the action of cAMP and cGMP. An en-
zyme with PDE activity was isolated from the choanoflagellate Sal-
pingoeca rosetta almost at the same time by the Kandori and the Oprian
groups (Lamarche et al., 2017; Yoshida et al., 2017). The Rh-PDE or
RhoPDE, as it was named by the different groups, is a fusion of rho-
dopsin type I with PDE. The enzyme displays only a minimum amount
of light-dependent PDE activity and can hydrolyze both cyclic nucleo-
tides constitutively in the dark, but with higher selectivity for cGMP
over cAMP (Lamarche et al., 2017; Yoshida et al., 2017). Crystal-
lography of the isolated PDE domain of the enzyme showed high re-
semblance in terms of sequence and structure to the human PDE9
(Lamarche et al., 2017). Future research will provide better insight in
the function of this unique fusion protein and its potential use as op-
togenetic tool in modulating cyclic nucleotide signaling.
13. Discussion
The above studies indicate that development of treatments targeting
the cyclic nucleotide signaling cascades could be a promising approach
for combating memory impairments. Nevertheless, it is still a matter of
intense investigation which components should be targeted in memory-
related diseases. Proper memory formation is based on a well-orche-
strated balance between production and degradation of cyclic nucleo-
tides, as well as, positive and negative feedback mechanisms. In AD, the
rationale for upregulating the AC-cAMP-PKA/Epac or the sGC-cGMP-
PKG signaling cascades is based on the observation that CREB activa-
tion is negatively affected in the progression of the disease (Yamamoto-
Sasaki et al., 1999). Since these cascades promote CREB phosphoryla-
tion, they could represent a compensatory approach resulting in in-
creased phosphorylation of CREB. However, upregulation of a system,
even one that potentially possesses pro-cognitive function, does not
result in memory improvement per se. For example, genetic deletion of
Gia1, that inhibits adenylate activity in the hippocampus, enhances LTP,
but also results in severe memory deficits in several cognitive tasks
(Pineda et al., 2004). This result indicates that disrupting the “break” of
AC activity causes a saturation of cAMP production in the hippocampus
that leads to signal desensitization preventing formation of new
memory (Pineda et al., 2004). Similarly, overexpression of AC1 results
in impaired extinction of previously acquired memories which indicates
synaptic deficit (Wang et al., 2004). On the other hand, pharmacolo-
gical interventions like, for instance, preventing degradation of cyclic
nucleotides by PDE inhibitors seems to represent a more balanced ap-
proach in modulating cyclic nucleotide concentration and improving
cognitive function, yet caution is also needed here (see below; 53, 54).
A possible explanation could be that in the case of a genetic approach
there is complete depletion of a molecule, while in the case of phar-
macological intervention there is a partial inhibition/stimulation, thus
a more subtle influence on cellular signal transduction. Future studies
will have to reveal the exact role of cyclic nucleotide signaling cascades
in neuroplasticity and memory formation, as well as the full potential of
targeting the cyclic nucleotide signaling cascades in pathological con-
ditions.
Another important consideration is the altered biochemical signals
in a diseased or aged brain. As it was reported before, the PKA signaling
cascade appears over-activated in the prefrontal cortex of aged animals
(Arnsten et al., 2005). Therefore, mild activation of the cAMP/PKA
signaling cascade with cAMP-specific inhibitors or PKA activators could
exacerbate the cognitive performance related to prefrontal cortex.
Nevertheless, there is no evidence reporting a similar effect for Epacs.
Another line of studies showed that sGC responsiveness to NO is de-
creased in the temporal lobe of AD patients (Bonkale et al., 1995). A
possible approach to reduce the side effects of the disinhibited PKA
signaling cascade in the PFC and other adverse side effects could be
combination of drugs that act on different cascades. In this respect, it
was recently shown that co-administration of sub-efficacious doses of
PDE4 and PDE5 inhibitors could improve mnemonic process in phy-
siological conditions, but also rescue memory impairments in an animal
model for AD (Bollen et al., 2015; Gulisano et al., 2018). Additionally,
the usage of sGC activators could overcome the lack of sGC respon-
siveness encountered in diseases like AD. These observations indicate
the importance of taking into account age-related changes in expression
and function of cyclic nucleotide signaling molecules when developing
therapies for the treatment of memory diseases.
An integral part in the development of new therapeutic strategies is
the in-depth understanding of the molecular mechanisms conveying
memory processes. Development of new optical methods broadened our
knowledge regarding the physiological action and compartmentaliza-
tion of different molecules involved in the cyclic nucleotide cascades.
Despite the sensitivity of these techniques, they are usually im-
plemented in isolated cells or tissues. Although the cyclic nucleotide
cascades are presented conventionally to be linear, the relationship of
their signaling molecules deviates from linearity with the presence of
several positive or negative loops. Additionally, several isoforms of the
signaling components are characterized by region and even sub-cellular
specificity in their distributions. These characteristics impede accurate
prediction of the exact molecules that would be activated in a specific
brain domain upon administration of a drug that acts on the cyclic
nucleotide pathways. Therefore, the implementation of computational
models is eminent for integrating experimental data with other para-
meters including domain distribution, diffusional rates, interactions
with other pathways and enzyme kinetics for the cyclic nucleotides
E.K. Argyrousi, et al. Neuroscience and Biobehavioral Reviews 113 (2020) 12–38
30
signaling networks. For example, development of stochastic models was
used to reveal the temporal patterns by which CaMKII and PKA are
active during L-LTP and the importance of colocalization of PKA with
its downstream effectors in subcellular microdomains for maintenance
of L-LTP (Kim et al., 2010, 2011).Cyclic nucleotide signaling cascades
modulate a vast array of physiological and pathophysiological pro-
cesses via their regulation of the intracellular second messenger mole-
cules, cAMP and cGMP. Despite a century of research into exactly how
they exert their function in these processes, we are only starting to
comprehend their multifactorial interactions and the complexity of
signaling networks that they constitute in the brain. Emerging under-
standing of the functional roles of these cyclic nucleotide pathways in
compartmentalized signaling brain networks, together with the ongoing
development of the neuroscience tool box, including genetic models,
optical techniques and predictive computational models, provides great
potential for cyclic nucleotide signaling molecules to emerge as a pro-
mising target for the development of cognitive enhancing therapies for
several brain disorders, including memory dysfunction as observed in
AD patients.
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